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ABSTRACT 
ROLE OF CLINICAL AND BIOCHEMICAL PARAMETERS 
FOR PREDICTING OUTCOME OF NON - INVASIVE 
VENTILATION IN PATIENTS WITH ACUTE EXACERBATION 
OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
 
BACKROUND: 
NIV is applied to this group of patients suffering from increased work of 
breathing; we can reduce the duration of NIV and also prevent 
progression of this stage to acidosis. The key interest in our study is 
relating the outcome of NIV therapy with respect to association between 
respiratory rate, Electrocardiogram, Co morbidities, though previous 
others studies related the outcome NIV therapy with respect to arterial 
Ph and PaCO2. 
AIM OF THE STUDY: 
1. To know the correlation between compensated type 2 
respiratory failure patients with increased respiratory rate and 
work of breathing and NIV outcome (NIPPV success or failure) 
in a selected group of patients admitted in our hospital. 
 2. To evaluate the influence of parameters like sputum 
consistency, Electrocardiogram, Chest x ray and co morbidities 
on NIV therapy outcome in these selected group of patients.  
3. To find out whether sputum consistency modifies the duration of NIV 
therapy. 
RESULTS 
Total number of 131 patients was enrolled in this study of which females 
were 32.1% and males 67.9%. Mean age of enrollment in this study is 
54.85 (S.D + 6.248).  we record our finding that of 131 patients, 121 
patients got improved with NIV treatment and remaining 10 patients 
failed to improve due to various reasons which are discussed below. 
Mean duration of NIV to revoke patients with acute exacerbation and 
increased respiratory rate to near normalcy was 19.44 hours. Duration of 
NIV treatment is depends upon following factors: Respiratory rate at the 
time of admission, Sputum consistency, and Current history of smoking, 
Presence of co morbidities like Corpulmonale, diabetes and coronary 
artery disease. 
Conclusion: 
If NIV therapy is administered earlier in patients with acute exacerbation 
of COPD, we can certainly reduce the duration of NIV treatment, 
duration of hospital stay, and thereby reducing cost of treatment. 
We also strongly put forward that in patients with associated co 
morbidity failure rate is higher with NIV therapy and utmost care should 
be taken 
Keyword- COPD, Non Invasive Ventilation, work of breathing 
  
 
 
 
 
 
 
 
INTRODUCTION 
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Chronic obstructive pulmonary disease (COPD) is a form of 
chronic airway disease that develops mostly due to chronic exposure to 
noxious stimuli of which the most common is smoking [1]. 
The following are valid points about COPD: 
I. Complex mechanisms are involved in airflow obstruction, which 
leads to increased airway resistance. 
II. COPD can affect airway, lung parenchyma, pulmonary 
vasculature and the lesion can correlate to change in pulmonary 
function tests and clinical appearance.  
III. COPD is ranked fourth in worldwide case mortality rate and the 
disease is both treatable and preventable[1]. 
IV. Incidence of COPD is increasing year by year and many people 
die prematurely due to the disease or its complication. 
V. A unique programme to fight against COPD was developed in 
1998. This was known as global initiative for chronic obstructive 
lung disease with a cooperation of NIH, World health 
organisation and National Heart, Lung, Blood institute. Main aim 
of this initiative is to increase awareness about global burden of 
COPD, preventive measures involved and management of COPD. 
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According to WHO estimation in 2004, there were about 64 million 
people affected by COPD worldwide [2]. In the year 2005, case fatalities 
due to COPD accounts for about more than 3 million people, which is 
approximately around 5% of all death globally that year. Almost 90 % 
of deaths occurred in low and middle income group countries.Without 
any intervention to cut down the risk factors related to COPD, total 
death may increase by more than 30% in the next 10 years. 
The recent study “Indian Study of Asthma, Respiratory Symptoms 
and Chronic Bronchitis” (INSEARCH) conducted from 12 urban and 11 
rural sites which includes  85,105 men and 84,470 women reported that 
prevalence of chronic bronchitis is 3.49% (4.29% in males and 2.7% in 
females) in adults > 35 years, the national burden was 14.84 million [3] 
 INSEARCH study used questionnaire and Spirometry, hence 
itcorrelates poorly with symptoms. The drawback of this study is that it 
might miss asymptomatic individuals with earlyspirometric 
abnormalities which might be significant. 
Another COPD prevalence study conducted in Pune by using post 
bronchodilator Spirometry and questionnaire, reportednearly 2-fold 
higher prevalence compared to INSEARCH study.  
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Another collaborative study conducted in rural Kashmir with 
subjects aged more than 40 years by applying BOLD protocol, 
concluded that the prevalence of Stage1 or higher COPD was 19.3% [4]. 
Clinical diagnosis of COPD is considered in patients who presented 
with chronic cough, breathlessness, increase in amount of sputum 
production, and exposure to causative factors for this disease. 
Spirometric lung function test is needed for diagnosis. The presence of 
obstructive lung disease is diagnosed by post bronchodilator FEV1/FVC 
<0.70 and the severity of disease is assessed by Post bronchodilator 
FEV1. 
COPD assessment is important because it helps to assess severity of 
disease, predicts hospital admission, or death and risk of subsequent 
exacerbation.  
Exacerbation of COPD is defined as“asustained worsening of the 
patient’s condition, from stable state and beyond normal day-to-day 
variations, that is acute in onset and necessitates a change in regular 
medication in a patient with underlying COPD”. 
Acute exacerbation of COPD is due to either viral infection of upper 
respiratory tract or infection of the conducting airways like 
tracheobronchitis.The aim of treatment in COPD patients with acute 
exacerbation is to reduce current exacerbation and also to prevent the 
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development of further exacerbations. Medications used during acute 
exacerbation includes short acting beta 2 adrenergic agonists with or 
without anti cholinergic drugs. 
COPD exacerbation can be prevented by simple measures like 
cessation of smoking, vaccination against influenza and pneumococcus, 
knowledge about how to use inhaled medication and treatment with long 
acting drugs such as anti cholinergics and beta 2 adrenergic drugs with or 
without inhaled form of corticosteroids. These measures reduce the 
number of acute exacerbations and hospitalization. 
 DONALDSON et al [5] study reported highest number of annual 
exacerbations occurring in patients with severe COPD (category III) 
than in patients with moderate COPD.  
PAGGIARO et al. [6] predicted exacerbations based on FEV1, in 
which they found that patients with forced expiratory volume (FEV1) 
>60% had 1.6±1.5 (mean±SD) exacerbations per year. It is increased to 
1.9±1.8 in patients with post bronchodilator  FEV1 value between 59%–
40%  and 2.3±1.9 exacerbations in patients with post bronchodilator  
FEV1 <40% predicted. 
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According to GOLD guidelines, indication for non-invasive 
mechanical ventilation in acute exacerbation of COPD includes [1]:  
1. Respiratory acidosis (arterial pH < 7.35 and / or PaCO2>6.0 kPa, 
45 mmHg). 
2. Severe dyspnoea with clinical signs characterized by fatigue of 
respiratory muscles, maximized work of breathing or both such as 
increased activity of accessory muscles, abdominal paradox, or 
intercostal muscle indrawing. 
Guidelines for respiratory failure management in acute 
exacerbation of COPD are mainly based on arterial blood gas analysis. 
Failure and success of Non-invasive ventilation depends upon arterial 
pH. Among hospitalized patients with COPD majority suffer from 
increased work of breathing and a few percentages of patients are 
admitted with acidosis which occurs following long standing untreated 
increased work of breathing leading to need for mechanical ventilation. 
When NIV is applied to this group of patients suffering from increased 
work of breathing, we can reduce the duration of NIV and also prevent 
progression of this stage to acidosis. The key interest in our study is 
relating the outcome of NIV therapy with respect to association between 
respiratory rate, Electrocardiogram, Co morbidities, though previous 
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others studies related the outcome NIV therapy with respect to arterial 
Ph and PaCO2.  
Another important reason behind my interest in this study is to 
compare the association of sputum consistency and smoking duration of 
NIV therapy. This forms the basis for selection of   group with increased 
work of breathing who had been hospitalized and studying the outcome 
of NIV on them.  
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COPD is a disease characterized by limitation of airflow that is 
not fully reversible even after treatment. The airflow limitation 
associated with an abnormal inflammatory response of the lungs to 
noxious particles and gases. COPD is usually a progressive disease. 
 
Risk factors leading to COPD include genetic and environmental 
factors. 
Risk Factors for COPD: 
Environmental  Host based  
Smoking Genetic factors  
Occupational exposure Airway hyper reactivity 
Air pollution  
Childhood respiratory 
infection 
 
Low socioeconomic status  
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Environmental factors 
Smoking is the most important risk factor for development of 
obstructive lung disease [7].  
Other factors include outdoor air pollution, dusts and fumes 
exposure in occupational environment, inhalation of biomass smoke, 
second –hand smoke exposure and previous tuberculosis. 
Tobacco smoking 
A Swedish cohort study [8] and Denmark study[9] reported that 
population attributablerisk fordevelopment of COPD in smokers 
respectively as 76.2% and 74.6%. In India most of them are using 
“BEEDI”for smoking more than cigarette[10]. Compared to non-smokers 
ventilatory function, deterioration is common among smokers. In males 
average decline in FEV1 is approximately around 9 ml per year for each 
pack-year of smoking and for female it is 6 ml.  8-yr prospective study 
of working men in West London by Fletcher and Petoshowed that fall in 
FEV1 in smokers will be faster than in non-smokers. 
The study conducted among middle aged smokers with anFEV1 
between 55 to 90 %of predicted (The Lung Health Study) [11] revealed 
that those who quit smoking will have an improvement in FEV1 around 
200 ml compare to non-smoker within 5 years. 
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Occupation: 
            Chronic inhalation of particles and gases carries a greater risk for 
COPD. Although we are not able to estimate the correct prevalence of 
COPD among workers because most of the workers are smokers and 
those with COPD drop out from work. The American Thoracic Society 
states that 15% of COPD cases are due to occupational exposure. The 
incidence of COPD among construction workers, plastic manufacturing 
and utility workers has also been found to be increased.  
Outdoor air pollution: 
It is due to pollutants from industries and motor vehicles causing 
pathological changes in lung and airway. A previous study observed that 
higher traffic density is associated with increased risk of COPD in 
women. Ozone, nitrogen dioxide and particulate pollutants [12] may 
cause bronchial hyperactivity, airway oxidative stress, pulmonary and 
systemic inflammation. 
Indoor air pollution: 
Biomass smoke and environmental tobacco smoking exposure 
contribute to the development of COPD. Biomass (animal dung, crop 
residue and wood) are used for cooking in rural areas. The Meta analysis 
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shows that biomass exposure is associated with development of COPD 
in both men and women[13]. 
Childhood Lower Respiratory Tract Infections: 
Since lung growth and alveolar development continues into early 
childhood, it is possible that lower respiratory tract infections during 
childhoodmight produce permanent damage or impair lung growth and 
development[14]. 
HOST FACTORS 
Genetic factors 
Polymorphisms of genes involved in protease- antiprotease 
balance, antioxidant function, inflammation,and immune responses have 
been implicated inCOPD. 
 In one study, a combination of both candidate gene and positional 
cloning approaches were used.  Boston Early-Onset COPD study [15] 
evaluated a single nucleotide polymorphism (SNPs) in and around the 
transforming growth factor-ȕ1 (TGF-ȕ1) region located in chromosome 
19q and found that it was linked to pre-bronchodilator FEV1in smokers. 
This study was later confirmed by National Emphysema Treatment Trial 
(NETT),which includes not only the initial phenotype of low pre-
bronchodilator FEV1, but also the presence of radio graphically 
confirmedemphysema. 
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Alpha 1 antitrypsin deficiency[16] causes COPD mainly in the young 
individuals, which accounts for about 1-2 % of total causes of COPD. 
Conditions suggesting alpha 1 anti-trypsin deficiency: 
1. Early onset emphysema (age less than 45 years). 
2. Emphysema in a non-smoker. 
3. Emphysema predominantly in lung bases. 
4. Family history of early onset emphysema or non-smoking related 
emphysema. 
5. Bronchiectasis without any other aetiology. 
Airway hyperresposiveness: 
In COPD, airway hyper-responsiveness is associated with 
accelerated decline in FEV1.However airway hyper-responsiveness does 
not predict bronchodilator responsiveness.   
Pathological changes: 
Clinical features of COPD are mainly due to complex alterations 
in structure and function of small airways and alveolar tissues. Processes 
implicated in development of pathological changes includes 
inflammation, cell proliferation, apoptosis, altered phenotype of lung 
cells, and remodelling of the extracellular matrix. 
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Inflammation: 
Inflammation occupies a central role in pathogenesis of COPD. 
Smoking and other type of inhaled particles cause recruitment of 
inflammatory cells to the lungs and airways leading to lung injury and 
disrupt the normal mechanism of lung repair. Inflammatory cells 
associated with lung injuries are neutrophils, eosinophils, macrophages, 
and lymphocyte. 
Broncho alveolar lavage fluid collected from smokers contains 
many fold increase in macrophages compare to non-smokers [17]. Up 
regulation of macrophage inflammatory protein-1Į (MIP-1Į), 
interlukin-8(IL-8), interlukin-13(IL-13), Ȗ-interferon, and monocyte 
chemo attractant protein-1(MCP-1) is seen in bronchial epithelium of 
COPD patients. Cellular and humoral immunity play a central role in 
pathogenesis of emphysema. 
Proteinase-Antiproteinase imbalance: 
Several proteinases are involved in pathogenesis of COPD. Serine 
proteinases, especially neutrophils elastase, and several matrix 
metalloproteinases especially collagenase, gelatinase B, macrophage 
elastase, and MMP-14 are involved in pathogenesis of COPD [18]. 
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Oxidant-Antioxidant imbalance [19]: 
Smokefrom cigarette causes release of free radicals like Reactive 
oxygen species by inflammatory cells leading to lung injury. Up to 20 
mg of tar per cigarette may be deposited in lung during smoking.Per 
gram of tar contains (10) 17stable, long living radicals. In vitro study 
done by Schaberget al (11) showed that airway neutrophils and alveolar 
macrophages generate more oxygen free radicals such as hydrogen 
peroxide, hydroxyl radicals, and superoxide radicals in smokers than 
non-smokers. 
Smoker’s lung has more iron than that of non-smokers, providing 
catalyst for the production of hydroxyl radicals from H2O2. Oxidants 
can modify and inactivate protein such as alpha 1 antitrypsin, secretory 
leucoprotease inhibitor [SLPI], and histone deacetylase 2(HDAC2), 
which is involved in glucocorticoid mediated anti-inflammatory 
responses. Free radicals mainly affect the polyunsaturated fatty acids in 
the cell membrane. Compared to non-smokers, bronchoalveolar lavage 
fluids of smokers have increased levels of products of lipid 
peroxidation. 
Anti-oxidants will give protection against oxidative injury. Intracellular 
anti-oxidants are controlled by copper and zinc dependant superoxide 
dismutase found in the cytoplasm and a manganese dependant form in 
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mitochondria. H2O2 is eliminated by catalase and glutathione 
peroxidase.  
Additional anti-oxidants are vitamin A and vitamin E, which are 
enriched in epithelial lining fluid. 
Experimental evidence shows that mice which lack anti-oxidant 
regulator, nuclear factor E 2-related factor (NȖf-2) develop emphysema 
when they are exposed to cigarette smoking. NȖf-2 protects against the 
development of emphysema not only by regulation of oxidant – anti 
oxidant balance, but also reduces the airway inflammation and maintains 
protease anti proteases balance.  
Apoptosis: 
  Kasahara et al, Tuder et al study showed that apoptosis has an 
important role in COPD pathogenesis. Recent study suggests that 
vascular endothelial growth factor (VEGF) signalling in alveolar 
endothelial cells or genetic down regulation of VEGF production in 
alveolar epithelium produces apoptosis [20]. The mechanism by which, 
apoptosis leads to emphysema is still not clear. In Caspase 3 animal 
study which shows that apoptotic cell found in smoker lung and 
emphysematous lung not in non-smoker. That apoptotic alveolar type 2 
cells degraded elastin. 
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Mucus hyper secretion: 
Mucus is secreted from sub mucosal glands and airway goblet 
cells. Mucus glycoprotein is the main component of mucus, which has 
core proteins such as serine and threonine, to which carbohydrate and 
Cysteine residues are attached. In COPD mucus secretion is altered 
leading to hyper secretion of MUC5B over typical MUC5AC form and 
increase in MUC2 form. Other changes in mucus layer include greater 
acidity, less mucus glucosylation, and decreased anti-microbial peptides. 
GOLD stage severity was strongly correlated with inflammatory cell 
infiltration in small airway than the luminal mucus hyper secretion  
PATHOGENESIS OF COPD[21]: 
Elastase-Antielastase hypothesis: 
Lung elastic fiber 
    Destruction of lung elastic fibres is a key component in development 
of emphysema. Extracellular matrix of lung parenchyma is organized as 
1.axial system 2.parenchymal system 3.peripheral system. 
Axial system extends from central airway to alveolar ducts, 
Parenchymal system is formed by matrix of alveolar septae, and 
Peripheral system arises from visceral pleura and extends into alveolar 
septae. Distal to respiratory bronchiole, axial system forms helix 
encircling alveolar duct. Elastin is the main component of axial system 
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and these elastic fibres provide elastic recoil throughout respiratory 
cycle. Elastin is resistant to many proteinases, however many enzymes 
are capable of degrading elastin such as neutrophils elastase, proteinases 
3, cathepsin G, MMP-9, MMP-12, cathepsin L and cathepsin S. 
Lung collagen turnover: 
Alveolar wall collagen degradation and abnormal collagen 
deposition in alveolar wall are involved in pathogenesis[22].  Because  of  
interstitial lung collagenous degradation produces enlargement the pores 
of kohnand produces emphysema. In emphysematous lung the number 
of pores of kohn is high. 
Proteinases-Antiproteinase imbalance: 
Proteinases such as Neutrophil elastase, Matrix Metalloproteinase 
and Cysteine Proteinase are involved in pathogenesis of emphysema. 
Neutrophil elastase is stored in azurophilic granules as an active protein; 
Serine Proteinase plays a prominent role in pathogenesis of COPD. It is 
active against elastin and other extra cellular matrix as well as non-extra 
cellular matrix. 
Matrix Metalloproteinase (MMPs) [23] 
This family of enzymes is divided into two types based on site of 
secretion and membrane association. MMPs degrade extracellular 
matrix and modify many other substances. Membrane bound forms are 
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more resistant to inhibition to Antiproteinase than MMPs in pericellular 
spaces. MMP-8 and MMP-9 are stored in specific granules in 
neutrophils. Alveolar macrophages produce MMP2, 9, 12, and 14. 
Cysteine proteinases: 
Human alveolar macrophage produces cathepsin L and S. These 
enzymes work at acidic pH, but at neutral pH, cathepsin S retains about 
25% of its elastolytic capacity, which is equivalent to action of 
neutrophils elastase activity. 
Proteinases inhibitor: 
Inhibitors of serine proteinases and tissues inhibitors of Matrix 
Metalloproteinase of COPD which includes both Chronic bronchitis and 
Emphysema. 
Emphysema is defined as an enlargement of the air spaces distal 
to the terminal bronchioles, with destruction of their walls. Secondary 
pulmonary lobule is the functional unit of lung. 
Centrilobular Emphysema 
 In centrilobular emphysema, initial site of destruction leading to 
development of emphysema is pores of kohn. In classical lesion 
respiratory bronchioles appears dilated and enlarged, alveolar duct and 
alveoli appears normal. Centrilobular emphysema commonly affects 
upper zone. Most affected segment is apical & posterior segment of 
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upper lobe and superior segment of lower lobe. In cases of severe 
Centrilobular emphysema, the destruction mayproceedtowards the 
periphery of the lobule, so that distinction between centrilobular and 
paraseptal emphysema because blurred.  
Panlobular Emphysema 
In panlobular emphysema distinction between alveolar duct and 
alveoli is lost& alveoli lose their sharp angles. The pores of Kohn are 
more uniform and inconspicuous than in centrilobular emphysema. Mild 
panlobular emphysema is difficult to diagnose. Pan lobular emphysema 
is seen in patients with alpha1 antitrypsin deficiency, constrictive 
bronchiolitis, and obliterative bronchiolitis. Panlobular emphysema 
affects the lower lobe predominantly. 
Paraseptal Emphysema 
More distal part of the acinus is affected like alveoli and alveolar 
duct, emphysema is adjacent to the pleura, along lobular septa 
(paraseptal emphysema) and at the margins of lobules and acini. 
Irregular Emphysema: 
Irregular emphysema is almost invariably adjacent to a scar, so it 
is otherwise called as paracicatricial emphysema. Most scars within 
lungs are small so emphysema is limited in extent. 
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Chronic Bronchitis 
In chronic bronchitis inflammation involves epithelium of central 
airway and mucus secreting cells. This inflammation leads to increased 
mucus secretion and decreased mucociliary clearance.  
Diagnosis of COPD: 
Physical examination and chest imaging are insensitive methods 
for diagnosis of COPD. Physical findings such as decreased breath 
sound; hyper resonant chest percussion and low lying diaphragm are 
specific for COPD. The distance between thyroid cartilage and sternal 
notch less than 4 cm in a smoker older than age 45Yrs is highly 
suggestive of the presence of COPD. 
Dyspnoea is seldom a compliant until FEV1 falls below 60% of 
predicted. 
Hyperinflation is common in moderate and severe COPD, it 
produces increase in residual volume and also increased ratio between 
residual volumes to total lung capacity. Hyperinflation may be 
beneficial in COPD by increasing lung volume, elastic recoil pressure, 
and also decreasing airway resistance there by preserving maximum 
expiratory airflow. 
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Hyperinflation causes increase in dyspnoea by:  
1. Decreased apposition between the muscles of abdomen and the 
diaphragmatic muscle. 
2. Flattening of diaphragm causes increased radius of curvature, 
thereby decrease in transpulmonary pressure. 
3. Shorter diaphragm muscle fiber length causes decrease in the 
force of contraction.  
During exercise hyperinflation worsens because of airflow 
obstruction during expiration. HIV/AIDS is also associated with 
premature emphysema. 
Lung volume measured by helium dilution method and nitrogen 
washoutplethysmography shows elevated total lung capacity and 
residual capacity. The carbon monoxide diffusion capacity is decreased 
in patients who have an FEV1 less than 1.0 L. 
Clinical features: 
Physical findings usually appear in severe form disease only. 
INSPECTION FINDINGS: Pursed lip breathing, barrel shaped chest 
(increase in anteroposterior diameter of the chest), Hoover sign-- 
flattening of diaphragm produces contraction of muscles which causes 
inward movement of the chest wall. 
PALPATION:  Reduction in the movement of the chest. 
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PERCUSSION: Tympanic note heard due to hyperinflation of the lung.  
AUSCULTATION: Decrease in respiratory sounds and expiration is 
prolonged, polyphonic wheeze during expiration. 
Chest X Ray finding: 
Postero-Anterior view: 
1. Increased radiolucency. 
2. Decreased peripheral blood vessel shadows. 
3. Flattening of diaphragm. 
4. Decreased cardio-thoracic ratio- cardiac diameter less than 
11.5cm with vertical heart and lung seen below the heart. 
5. Increased intercostal space. 
Lateral view: 
1. Increase in retro cardiac space. 
2. Increased in retrosternal area- measurement taken between anterior 
aspect of ascending aorta and the posterior aspect of sternum 3 cm 
below manubriosternal joint. 
3. Obtuse costophrenic angle. 
Computer tomography: 
CENTRILOBULAR EMPHYSEMA: ill-defined margin with areas of 
low attenuation area. In early stage of COPD usually affects upper 
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zone of lung, low attenuated areas closely related to centrilobular 
arteries. Lung surrounding the low attenuated area appears normal. 
PANACINAR EMPHYSEMA: lung destruction is uniform and gives 
rise to generalize low attenuation density of lung. Panacinar 
emphysema affects the lower lobe predominantly.  
PARASEPTAL EMPHYSEMA: sub pleural well-marginated low 
attenuation area with distinct hairline walls. This pattern resembles saw 
teeth appearance. 
Emphysema can be assessed by using lung density index. In Gevenios 
et al study among COPD patients showed density of -950 HU 
providing an accurate estimation of COPD. 
Goddard classification of COPD[24]: 
1 point: scattered emphysematous lesion 1 cm or less in diameter. 
2 point: large size Low Attenuation Area (LAA) due to the fusion of 
emphysematous lesions. 
3 point: LAA occupies an even larger area by the more pronounced 
fusion.  
4 point: most of the lung occupied by emphysema and only a small 
area of normal lung. 
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Visual evaluation of pulmonary emphysema [25]: 
Right and left lung divided into six areas by upper, middle, and 
lower lung fields on both sides. Degree of severity of pulmonary 
emphysema is graded based on five-point scale 
0 point: no emphysematous lesions. 
1 point: occupies less than 25 % of the entire lung field. 
2 point: occupying from 25% to less than 50% of the entire lung field. 
3 point: occupying from 50% to less than 75% of the entire lung field. 
4 point: occupying more than 75 % of the entire lung field. 
Maximum total = 24 points.  
Spirometric assessment: 
Spirometry is essential for diagnosis of COPD, classification of 
severity and progression of the disease. For the diagnosis, post 
bronchodilator FEV1/FVC should be less than 0.70. Once airflow is 
established, the severity of the disease is based on the FEV1. 
Classification of COPD severity  
Stage Characteristics 
Mild COPD FEV1> 80% predicted 
Moderate COPD FEV1 50%- 79% predicted 
Severe COPD FEV1 30%-49% predicted 
Very severe COPD FEV1 < 30 % predicted  
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BODE index: 
Body mass index, Obstructive ventilatory defect severity, Dyspnoea 
severity, and Exercise capacity [26] 
Variable 
Points On the BODE Index 
     0        1        2        3 
FEV1(% predicted ) >65 50-64 36-49 <35 
Distance walked in 6 
min(in meters) 
>350 250-349 150-249 <149 
MMRC dyspnoea scale 0-1     2      3      4 
 Body mass index >21 <21   
 
2 year mortality in patients with BODE score greater than 7 is 30%; 
whereas score of 5 to 6 is associated with 15 percent mortality. Score 
less than 5 is associated with 10% mortality in 2 year period. 
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Assessment of symptoms: 
In the past COPD was assessed mainly based on severity of 
breathlessness, so MMRC grading was in use. Now COPD is recognized 
as multisystem disease, so to assess the comprehensive symptom, two 
questionnaires were developed such as 1. CAT questionnaire (COPD 
Assessment Test) and 2.CCQ (COPD Control Questionnaire) which are 
in current use. 
COPD Assessment Test[27]: 
This test has an 8- uni dimensional measure to assess health status 
of COPD patient. CAT questionnaire is available in local languages and 
also through validated translations. Test very closely correlates with the 
SGRQ (St George’s Respiratory Questionnaire) 
COPD Control Questionnaire (CCQ): 
CCQ has 10 items in questionnaire which can be self-
administered and developed to assess clinical control in patients with 
COPD. 
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Assessment of Exacerbation Risk: 
The best predictor of having frequent exacerbation is a history of 
previous events of treatment. Hospitalization for a COPD exacerbation 
has poor outcome and also increased mortality. 
RISK OF COPD: placebo-limb data from TORCH[28], Uplift and 
Eclipse: 
 
Assessment of co morbidities: 
COPD is a multi-system disease, so it has significant extra 
pulmonary effects such as loss of weight, nutritional deficiency and 
skeletal muscle dysfunction due to enhanced anaerobic metabolism. 
 
 
GOLD 
spirometric 
level 
Exacerbations 
per year 
Hospitalizations 
per year 
3 year 
mortality 
Mild         ?           ?         ? 
Moderate   0.7 – 0.9   0.11 – 0.2         11% 
Severe   1.1 – 1.3   0.25  - 0.3         15% 
Very severe   1.2  - 2.0   0.4  - 0.54          24% 
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Co morbidities associated with COPD patients: 
Because of common risk factors, COPD patients will have more 
number of co morbidities like   cardiovascular disease, atherosclerosis, 
hypertension, depression, pulmonary embolism and lung cancer. 
Comorbidity occurrence is independent of severity of airflow limitation 
which can occur at any stage of the disease. 
Factors associated with poor survival in COPD 
i. Low FEV1. 
ii. Active smoking. 
iii. Hypoxemia. 
iv. Poor nutrition. 
v. Presence of Corpulmonale. 
vi. Resting tachycardia. 
vii. Low exercise capacity. 
viii. Severe dyspnoea. 
ix. Poor health related quality of life. 
Reduction of the inspiratory capacity has a prognostic significance that 
is independent of FEV1. 
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Management of stable COPD: 
Once COPD is established, treatment should be based on individual 
disease severity. 
Goals for treatment of stable COPD  
Reduce symptoms: 
1. Relieve symptoms. 
2. Improve exercise tolerance. 
3. Improve health status. 
Reduce risk: 
1. Prevent disease progression. 
2. Prevent and treat exacerbation.  
3. Reduce mortality. 
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Non pharmacological management of COPD 
Patient 
group 
Essential recommended Depending on 
local guidelines 
       A Smoking cessation 
(can include 
pharmacologic 
treatment) 
Physical 
activity 
Flu vaccine 
Pneumococcal 
vaccine 
      B-D Smoking cessation 
(can include 
pharmacologic 
treatment) 
Physical 
rehabilitation 
Physical 
activity 
Flu vaccine 
Pneumococcal 
vaccine 
 
Reduction in exposure to risk factors: 
Smoking: 
Smoking is the culprit for the development of COPD, so cessation 
of smoking is the main goal for all COPD patients. Health care 
professional should provide information regarding smoking cessation 
messages. 
 
 
 
 
31 
 
Behavioural approaches: 
 Popularly referred as “the five A’s”--- Ask, Assess, Advice, Assist, 
Arrange. 
Group counselling: 
These programs includes lectures, group interactions and 
exercises on self-recognition of one’s habit 
Gradual reduction VS Abrupt Abstinence: 
In gradual reduction phase when their nicotine level falls below 
critical threshold level patients experience tobacco withdrawal 
symptom, and prolonged discomfort. Many taperers gradually return to 
their customary cigarette smoking level. 
Abrupt abstinence will also experience tobacco withdrawal symptoms. 
After few weeks of complete abstinence they experience less frequent 
cigarette craving than gradual taperers. 
Pharmacologic treatment: 
1. Nicotine replacement therapy. 
2. Drugs.  
3. Nicotine vaccine.  
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Nicotine replacement therapy: 
Varieties of nicotine replacement formulations are available in 
market. They are Polacrilex (gum), trans-dermal system, nasal spray, a 
variety of inhalers and nicotine toothpicks.  
Drugs like bupropion and varenicline used in smoking cessation. 
Bupropion as an antidepressant [29], it is believed to act through 
dopaminergic and noradrenergic signalling. Recommended dose is 150 
mg daily for 3 days followed by 150mg twice daily. 
Varenicline is an (alpha4)3(beta2)2 receptor partial agonist [30]. It 
inhibits and blocks some nicotine effect. As a partial agonist, it has the 
potential to mitigate some of the nicotine withdrawal symptoms. 
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                               Pharmacological drugs for COPD  
Patient 
group 
Recommended first 
choice Alternative choice 
Other possible 
treatment 
 
 
 
A 
Short- acting 
anticholinergic 
        or      
short- acting beta2-
agonist 
Long –acting anticholinergic 
        Or 
Long-acting beta2-agonist 
       Or 
Short-acting beta2agonist 
and short-acting 
anticholinergic 
 
 
 
Theophylline 
 
B 
Long-acting 
anticholinergic 
        Or 
Long acting beta2-
agonist 
Long acting anticholinergic 
and long-acting beta2agonist 
Short-acting 
beta2-agonist 
    And/or 
Short acting 
anticholinergic 
Theophylline 
 
 
 
 
C 
Inhaled 
corticosteroid 
+long acting beta2-
agonist 
      Or 
Long-acting 
anticholinergic 
Long acting anticholinergic 
and long acting beta2agonist 
     Or  
Long acting anticholinergic 
and phosphodiesterase-4 
inhibitor 
         Or 
Long acting beta2-agonist 
and phosphodiesterase-4 
inhibitor 
Short acting 
beta2-agonist 
And /or 
Short acting 
anticholinergic 
 
Theophylline 
 
 
 
 
D 
Inhaled 
corticosteroid+ 
Long acting 
beta2agonist and/or  
Long-acting 
anticholinergic 
Inhaled corticosteroid+ 
Long-acting beta2-agonist 
and long-acting 
anticholinergic 
       Or 
Inhaled corticosteroid+ long 
acting beta2agonist and 
phosphodiesterase-4 
inhibitor 
        Or 
Long-acting anticholinergic 
and long-acting beta2agonist 
Carbocysteine 
 
Short acting 
beta2agonist  
And /or 
Short acting 
anticholinergic  
 
Theophylline 
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Pharmacologic treatment: 
Pharmacologic treatment for COPD will reduce symptoms, 
increase exercise tolerance, decreases the number of episodes and 
severity of exacerbation, thereby improving the wellbeing. But 
pathogenesis of COPD and the long term decline in lung function is 
unaltered by above drugs. 
When drugs are given through inhaled route proper training about 
technique is essential for management. The inhaler therapy prescription 
depends upon the availability of drug, the skills and ability of the 
patient, cost, and the prescribing physician. 
Bronchodilators: 
Bronchodilators will improve the FEV1 by modifying tone of the 
airway smooth muscles, by this expiratory flow is improved by airway 
widening. So it reduces dynamic hyperinflation during exercise and rest. 
Toxicity is dose related. 
Inhaler therapy is preferred, in which long acting bronchodilator 
is more efficacious than short acting drugs. Bronchodilators play central 
role in symptomatic management in COPD patients. Combination of   
different classes of bronchodilator drugs will improve efficacy and 
decrease the adverse effects. 
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Anti-cholinergic drugs: 
Most commonly used drugs are ipratropium, oxitropium, 
Tiotropium. These drugs block the acetylcholine, and act on muscarnic 
receptors. Short acting drugs block M2, M3 receptors andpre-ganglionic 
junctional transmission is modified. Long acting drugs block M3 and M1 
receptors. Anti-cholinergic drugs act longer duration than beta2 agonists. 
Those with short action have 8 hours of bronchodilator activity and long 
acting has 12 hours of action [32].  
Beta 2-agonist: 
     Beta2agonist causes relaxation of smooth muscle present in the 
airway mediated via beta2 receptors, causing increased cAMP. Short 
acting bronchodilators usually have 4 to 6 hours of action, long acting 
drugs have action of 12 or more hours. To improve the compliance of 
treatment long acting drugs are used once daily in the treatment of 
COPD. Study conducted by Gregory Feldman[31] shows 150 micro gram 
of once daily indacaterol is more compliant for the patients as well as 
less number of drop out. The only long acting beta agonist which has 24 
hours of action is Indacaterol. 
Study done by James et al[32] in COPD patients for comparison of 
Tiotropium and Indacaterol on trough FEV1 after 12 weeks of treatment 
and to evaluate safety and efficacy after 26 weeks of treatment. 
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They conclude that indacaterol more efficacious in 
bronchodilatation and has higher compliance than Tiotropium and 
placebo. 
Adverse effect: 
 1. Produces resting sinus tachycardia, and precipitate cardiac 
disturbance in some patients.  
2. Exaggerated somatic tremor. 
3. Hypokalemia. 
4. Tachyphylaxis. 
Methylxanthines: 
Xanthines act as non-selective phosphodiesterase inhibitors. 
Theophylline [34] produces bronchodilation by blocking adenosine 
action. It improves the diaphragmatic muscle contraction, prevents 
respiratory muscle fatigue, increases ventilatory drive andpotentiates 
catecholamine function. 
Theophylline decreases cough by augmenting mucociliary 
clearance, reduces the   late-phaseantigen responses, suppresses 
leukocyte activation, and inhibits of mast cell histamine release. 
Corticosteroids: 
The role of Corticosteroids in reduction of pulmonary and 
systemic inflammation is controversial, so use of corticosteroid alone in 
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management of stable COPD is not recommended. But some study 
demonstrates that regular use of corticosteroid will produce 
improvement in lung function, reducing the frequency of exacerbation; 
improving symptom, and quality of life. 
Adverse effect: 
Commonly encountered adverse effects of corticosteroids are Oral 
candidiasis, hoarseness of voice and skin bruising. Long term treatment 
is associated with osteopenia, and osteoporosis. 
Differential diagnosis: 
1. Bronchial asthma. 
2. Bronchiectasis. 
3. Diffuse pan bronchitis. 
4. Obstructive bronchitis. 
5. Congestive cardiac failure. 
6. Sino bronchial syndrome.  
Other treatments: 
Oxygen therapy 
In patients with hypoxemia, administration of oxygen for long 
duration (>15 hours in a day) improves their survival.  
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Long term oxygen therapy (LTOT) is indicated in the following 
conditions: 
1. PaO2 below 55 mmhg or SpO2 ator below 88% with or without 
hypercapnia confirmed twice over three week period. 
2. PaO2 between 55 mmhg and 60 mmhg or SpO2 of 88%, if there is 
evidence of pulmonary hypertension, polycythemia (hematocrit more 
than 55%) and congestive cardiac failure.  
Resting saturation of more than 70 mmHg at sea level is likely to be safe 
to fly without oxygen supplementation. If patients saturation is less than 
< 70 mmHg oxygen supplementation is essential while air traveling 
Surgical treatment: 
Lung volume reduction surgery (LVRS) 
LVRS is a surgical procedure by which 20 – 30% of lung mainly 
from apices is resected bilaterally. LVRS will reduce lung 
hyperinflation, making diaphragmatic muscles more effective pressure 
generators. LVRS increases the elastic recoil pressure so that it will 
improve the expiratory flow rate. Surgery is more effective in patients 
with upper lobe predominant emphysema and with low exercise 
capacity. 
Bronchoscopic lung volume reduction surgery in COPD patients 
with air flow limitation of FEV1 15-45% and heterogeneous 
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emphysema on CT, demonstrated moderate improvement in respiratory 
function. 
Lung transplantation: 
Lung transplantation will improve the quality of life in patients 
with very severe COPD. Lung transplantation is limited by donor organ 
shortage.  
Criteria for lung transplantation: 
BODE Index score of 7-10 in patients with age under 60 years and 
with at least one of the following criteria are indicated for lung 
transplantation. 
1) History of frequent exacerbation with a high PaCO2>50mmhg. 
2) Corpulmonale, pulmonary hypertension or both. 
3) FEV1<20% of predicted with DLCO<20% of predicted. 
Lung transplantation can be unilateral or bilateral depending upon 
the availability of donor lung. 
Presence of chronic hepatitis B or C infection, multi organ failure, 
current smoking and recent malignancy are considered absolute 
contraindications for lung transplantation surgery. 
Bullectomy: 
Bullectomy is a very old surgical procedure used to relieve 
dyspnea in patients with COPD. Excision of bullae that is not 
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contributing to gas exchange is known as bullectomy. Presence of high 
PaCO2, severe emphysematous lung and pulmonary hypertension are 
not a contraindication for surgery. 
Acute exacerbation of COPD: 
Defined as “A sustained worsening of the patient’s condition,from the 
stable state and beyond normal day-to-day variations, that is acute in 
onset and necessitates a change in regular medication in a patient with 
underlyingCOPD.” 
We should exclude other causes of worsening of symptoms like 
congestive cardiac failure, pneumothorax, and pulmonary embolism. 
Frequency and severity of acute exacerbation of COPD depends upon 
medication administration, smoking status, vaccination and disease 
severity.  
 Impact of acute exacerbation of COPD: 
1. Acute exacerbation of COPD will produces short term and long term 
impact on health status, the additional decline in FEV1 
averagedapproximately about 7 to 8 mL/year. 
2. Acute exacerbation of COPD is major source of health care 
expenditure, especially when patient is admitted for hospitalization. 
3. Recurrent episodes of acute exacerbation will affect the health related 
quality of life. Following single episode HQOL( Health-related Quality 
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Of Life) improves over 26 weeks, acute episode has negative impact on 
health related quality of life. 
Etiology of acute exacerbation: 
 1. Viral pathogens. 
 2. Bacterial pathogens. 
 3. Environmental exposure. 
Viral pathogens: 
Rhinovirus, Respiratory Syncytial Virus (RSV), and Influenza 
infection cause bronchial epithelial inflammation and elaborate various 
cytokines and inflammatory mediators (IL-8, GroĮ, and ENA-78) 
producing exacerbation of symptoms. In addition respiratory Syncytial 
virus and rhinovirus produceeotoxin, eotoxin-2, and CCL5.  Other viral 
causes include Parainfluenzae, Corona virus, Meta pneumovirus, and 
adenovirus. 
Bacterial pathogens: 
Bacterial pathogens causing acute exacerbation includes non-
typeable Haemophilus influenza, Moraxella catarrhalis, and 
Streptococcus pneumoniae, other infrequent causes include gram 
negative organisms likeHaemophilus parainfluenzaeand Pseudomonas 
aeruginosa, and gram positive organisms like Staphylococcus aureus. 
Soler et al  studied pathogenic growth from lower respiratory 
secretions of more severely ill patients with acute exacerbation treated 
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with mechanical ventilation by using protected specimen brush and 
BAL, and they identified bacterial pathogen in 42% of specimens and 
viral cause in 10% of patients. 
Bacterial infection causes increased mucus secretion, purulence of 
secretion, impaired mucociliary clearance and airway epithelial injury.    
Environmental factors: 
Both particulate and non-particulate matter for example sulfur 
dioxide, ozone, black smoke, and nitrogen dioxidecauses acute 
exacerbation of COPD. 
Evaluation of AE COPD: 
Clinical evaluation to identify the cause for exacerbation, and to 
rule out other causes for exacerbation like congestive cardiac failure, 
pneumothorax, and pulmonary embolism. 
Pathophysiology of acute exacerbation of COPD: 
The factors that favours Acute Respiratory Failure development during 
AECOPD depends on following: 
a) Severity of precipitating cause. 
b) Degree of physiological dysfunction. 
c) Subsequent physiological reserve. 
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FACTORS LEADING TO FATIGUE OF RESPIRATORY MUSCLE: 
Increased airway         Need for a high 
Resistance                                        minute ventilation 
 
 
 
 
Limitation of Expiratory flow rate 
 
Dynamic hyperinflation of lung 
 
Create an intrinsic positive end expiratory pressure 
 
Increased inspiratory threshold load to lung 
 
Respiratory muscle dysfunction 
 
FATIGUE 
 
Medical treatment                                     Maximize the lung function 
 
Reverse the precipitating causes 
 
 
Laboratory investigation: 
Chest X ray: 
It is used to identify the cause for exacerbation like Parenchymal 
infiltration, pneumothorax, cardiomegaly with pulmonary congestion 
and pulmonary embolism.  
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 Arterial blood gas analysis is used for assessment of oxygen 
status, carbon dioxide level and pH of blood to decide about treatment 
plan. 
Treatment: 
During acute exacerbation of COPD,an imbalance is created 
between respiratory load and capacity of the lung, producing 
exaggerated inflammation in the airways leading to spasm of bronchus, 
edema of   airways and more sputum formation. All this pathological 
changes will increase the airway resistance, and lead to increase in work 
of breathing. Patients tend to respond with rapid, shallow, largely 
ineffective breath, leading to increased dead space ventilation.  
Non-invasive ventilation 
Administration of positive or negative pressure ventilation to lung 
through either mask or similar device without intubation. NIV can be 
administered safely in ward itself; there is no need for intensive care 
unit. NIV decreases mortality in patients with acute exacerbation of 
COPD  with  arterial  pH  of  <  7.35,  PaCO2> 45mmhg (uncompensated 
respiratory failure) after medical management. It is indicated in these 
patients not responding to optimal medical management. 
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Based upon pressure delivered by non-invasive ventilator it is 
divided into two types: Negative pressure ventilation and Positive 
pressure ventilation. 
Till early 1960 only negative pressure ventilation was [35] used for 
NIV in patients with neuromuscular disorder likes poliomyelitis and 
deformity of chest wall. In this negativepressure was applied over chest 
through tank ventilator. Later positive pressure ventilation was in use for 
patients with respiratory failure. Initially positive pressure was given 
through endo tracheal tube alone. 
Non-invasive positive pressure ventilation: 
  Acute pulmonary edema patients got relieved of respiratory symptoms 
by giving continuous positive pressure ventilation, which was 
demonstrated by AlvanBarach[36]   in early 1930. By 1947, patients with 
acute respiratory failure where treated with intermittent positive pressure 
(IPP) ventilation. In NewYork (1960) Noninvasive positive pressure 
ventilation (NPPV) was administered nocturnally and in daytime it was 
used as and when neededin patients with neuromuscular disease 
atGoldwater Rehabilitation Center. Initially positive pressure was 
ventilation delivered through mouth piece.Later Nasal continuous 
positiveairway pressure (CPAP) was introduced in 1980sfor the 
treatment of obstructivesleep apnea. In 1984 Rideau and colleagues(19) 
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of Franceslowed disease progression of Duchene muscular dystrophy 
(DMD) using positivepressure ventilators which is confirmed by further 
studies which made NIPPV to gain importance in the treatment of 
chronic respiratory failure. 
Reason for our interest in Noninvasive Ventilation: 
Mostcommon reason for using non invasive ventilation is to avoid 
complication due to invasive ventilation. 
• NIPPV provides greater flexibility in initiating and removing 
mechanical ventilation. 
• While using NIV patient can eat, drink and communicate. 
• NIV does not produce any effect on airway defence, speech, and 
swallowing mechanisms. 
Complications due to invasive ventilation 
1. The process of intubation and mechanical ventilation like injury to 
teeth, upper aerodigestive tract, arrhythmia, and hypotension. 
2.  Loss of  airway defense mechanisms and impairmentof airway ciliary 
function facilitate an easy passage to themicroorganisms and other 
foreign materials to lower airways allowing their colonization leading to 
airway inflammation and damage. 
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3. After removal of the endotracheal tube- hoarseness of voice, sore 
throat, cough, sputum production, hemoptysis,upper airway obstruction 
and tracheal stenosis may occur. 
EQUIPMENT AND TECHNIQUES FOR NONINVASIVE 
VENTILATION 
In positive ventilation, available two modes are pressure-cycled 
and volume-cycled modes. In volume cycled mode [37] preset volume is 
delivered with each breath, irrespective of airway pressure. In volume-
cycled mode compliance of patient is poor and possibility of air leakage 
is high. 
 Pressure cycled mode is more used than volume-cycle mode 
because preset pressure can be delivered during both phases of 
respiratory cycle, which  can be either continuous positive airway 
pressure (CPAP) or bi-level positive airway pressure (BiPAP). 
In CPAP, mode preset pressure is applied both during inspiration 
and expiration. BiPAP gives a high flow positive airway pressure 
continuously, which cycles between high and low positive pressures.In 
this type, triggering factor is breath of the patient leading to flow 
initiation from the ventilator. Inspiratory positive airway pressure 
(IPAP) and expiratory positive airway pressure (EPAP)are two pressure 
types delivered by the machine.  
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A pre-set amount of pressure whichis delivered during inspiration 
is known as inspiratory positive airway pressure (IPAP). Expiratory 
positive airway pressure (EPAP) is reached by closing the expiratory 
limb of the ventilator circuit whenthe airway pressure is less than the 
pressure determined as EPAP. This EPAP maintains positive pressure 
during expirationin the airways which is similar to PEEP in 
conventional ventilator, preventing collapse of alveoli. 
Interfaces for the delivery of BiPAP or CPAP: 
Tight fitting silicone made mask forms the interface between the 
patient and the machine. It must be of correct size so that it fits 
properlyover bridge of nose and chin of the patient preventing air 
leakage. Steps must be taken to prevent development of pressure sores 
over bridge of the nose. 
Nasal masks: 
The nasal mask interface is preferred over other types of interface 
during chronic applications. Commonly used nasal mask is triangular or 
cone-shaped clear plastic device that fits over the nose and utilizes a soft 
cuff to form an air seal over the skin; Nasal masks are available in 
different sizes.  
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Nasal mask[38] exerts pressure over bridge of nose causing 
irritation, redness and rarely ulceration. Straps that hold the mask in 
place are also important for patient comfort 
Nasal “pillows” or “seals”: 
If the patient who develops claustrophobia or nasal bridge 
irritation due to nasal mask, the alternative nasal device used is nasal 
pillow. It consists of soft rubber or silicone pledgets that are inserted 
directly into the nostrils 
Oronasal masks: 
As the name suggests, oronasal mask covers both the nose and the 
mouth. It is used mainly in patients with acute respiratory failure 
because it prevents copious air leaking through the mouth which occurs 
using nasal mask ventilation. Oronasal mask can also be used for 
chronic respiratory conditions. 
Mouthpieces: 
It is simple and inexpensive. During the daytime, patients may receive 
ventilatory assistance via a mouthpiece attached to their wheelchair 
controls. 
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Goals of Non Invasive Ventilation: 
1. Relieve symptoms. 
2. Reduce work of breathing by decreasing trans- diaphragmatic 
pressure.  
3. Offset the effect of iPEEPby allowing the patient to take deeper 
breaths with lesseffort. 
4. Improve gas exchange. 
5. Minimize risk of barotraumas. 
6. Avoid intubation. 
Typical initial setting of non-invasive ventilation in patients with 
acute exacerbation of COPD[39] [40]: 
1. Mode – spontaneous timed. 
2. EPAP- 4 to 5 cmH2O. 
3. IPAP – 8 to 10 cmH2O (increase upto 20 cmH2O). 
4. Trigger-maximum sensitivity. 
5. Back up rate- 15 breaths/min. 
6. Back up I: E ratio- 1:3. 
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Indication for Non-invasive ventilation: 
I COPD 
1. Respiratory acidosis (PaCO2 >6.0 kPa, pH <7.35 or H+ >45 nmol/l) 
which persists despite maximal medical treatment and appropriate 
controlled oxygen therapy. 
2. Severe dyspnoea with clinical signs suggestive of respiratory muscle 
fatigue like increased work of breathing, use of accessory muscles, 
paradoxical motion of abdomen, and retraction of intercostal spaces 
3. Facilitates weaning of intubated COPD patients from mechanical 
ventilator. 
4. Extubation failure in COPD. 
II. Chest wall deformity, neuromuscular disorder, decompensated 
Obstructive sleep apnoea.  
III. Cardiogenic pulmonary oedema. 
Contraindication for NIV: 
1. Hemodynamic instability. 
2. Life threatening hypoxemia. 
3. Facial trauma/burns. 
4. Recent facial, upper airway, or upper gastrointestinal tract surgery. 
5. Fixed obstruction of the upper airway. 
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6. Inability to protect airway. 
7. Impaired consciousness. 
8. Copious respiratory secretions. 
9. Undrained pneumothorax. 
Predictor of NIV success in patients with respiratory failure: 
 Hypercarbia (PaCO2 < 92 mm Hg). 
 No Severe Acidosis, pH > 7.10. 
 Improvements in gas exchange and pulse rate and respiratory rate 
within first 1-2 hours. 
 Young age. 
 Lower acuity of illness (APACHE score). 
 Able to cooperate; better neurologic score. 
 When patient able to coordinate breathing with ventilator. 
 Less air leaking, intact dentition 
COMPARISON OF NIV AND INVASIVE VENTILATION: 
POINTS 
 
NIV INVASIVE VENTILATION 
Need and complications of 
intubation and tracheostomy 
   _    + 
Ventilation associated 
pneumonia 
  _    + 
Nosocomial infection   _    + 
Efficacy    =   = 
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AIM OF THE STUDY 
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AIM OF THE STUDY 
1. To know the correlation betweencompensated type 2 respiratory 
failure patients with increased respiratory rate and work of breathing and 
NIV outcome (NIPPV success or failure) in a selected group of patients 
admitted in our hospital. 
2. To evaluate the influence of parameters like sputum consistency, 
Electrocardiogram, Chest x ray and co morbiditieson NIV therapy 
outcome in these selected group of patients. 
3.  To find out whether sputum consistency modifies the duration of 
NIV therapy. 
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MATERIALS AND METHODS 
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SITE OF INVESTIGATION: 
Govt. Hospital of Thoracic Medicine, Tambaram Sanatorium, 
Chennai 
STUDY PERIOD: 
July2013 to July 2014 
STUDY DESIGN:  
Prospective observational study  
STATISTICAL ANALYSIS: 
By using Epi info7 software  
INCLUSION CRITERIA: 
1) COPD patients with acute exacerbation with PaCO2 > 45 
mmHg,pH (7.35 to 7.45) with increased work of breathing 
2) Age >18 years. 
EXCLUSION CRITERIA:  
1) Diagnosis of asthma, sleepapnea syndrome or respiratory             
failure not due to COPD. 
2)Patient with acidosis (arterial pH < 7.35). 
3) Patients with shock with a systolic blood pressure of < 90 
mmHg despite fluid challenge or need for vasopressor agents. 
4)Altered conscious state (GCS < 8).  
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5) Copious respiratory secretions that could not be cleared 
easilyby the patients. 
6) Recent myocardial infarction, unstable angina.  
7) Recent facial trauma. 
8) Upper abdominal surgery 
METHODS: 
1) Consecutive patients admitted with acute exacerbation of 
COPD with increased work of breathing and normal pH 
where recruited in this study. COPD was diagnosed with 
clinical examination, history, chest x ray finding, previous 
Spirometry. 
2) Thorough history about smoking pack years, occupation, 
duration of symptom exacerbation, wheeze history, clinical 
examination like measurement of respiratory rate, heart rate, 
blood pressure, work of breathing, accessory muscle activity& 
pulse oximetry for oxygen saturation. 
 3) Taking Chest x ray PA view to look for COPD changes, 
cardiomegaly, Parenchymal infiltration, and pneumothorax. 
ECG for Corpulmonale changes & to rule out ischemia. 
4) 1 to 2 ml of blood for haemoglobin estimation is collected to 
rule out anaemia and polycythemia.  
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5) Patient should be placed in a comfortable position and 
collect 2 ml of arterial blood from radial artery for blood gas 
analysis to assess PaCO2 level, PaO2, and pH. 
 6) Procedureexplained to the patient about administration of 
Non-invasive ventilation, whenever possible attendees should 
also be included in the discussion. 
 7) Assess patients’ heart rate, respiratory rate, blood pressure, 
sensorium, oxygen saturation, work of breathing and accessory 
muscle activity. 
8) Optimum medical therapygiven to all patients with acute 
exacerbation before initiating NIV which includes:  
 I. Controlled oxygen delivered to the patient to maintain arterial 
saturation between 88–92%. 
 II. Administration ofnebulised salbutamol in a dose of 2.5–5 mg mixed 
with distilled water followed by nebulised ipratropium 500 ȝg given. 
III.Prednisolone 30 mg tablet given through mouth, and antibiotic 
therapy if indicated. 
NIV should be administered in patients with respiratory failure 
inspite of optimum medical management for more than 1 hour. 
Before starting our study we ensured that the instruments are in 
working condition, proper motivation was given to patients to alleviate 
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their anxiety, nurses were given adequate training, tolerance of patient to 
mask ventilation was ensured, and possibility of air leakage in system 
circuit was checked. 
To improve psychological support, relatives of the patients were 
allowed to stay with them and assist them whenever they needed any 
help. This is considered important to gain patient confidence and 
motivate them in pursuing therapy. 
9)The patient was placed in a comfortable position like either 
sitting or semi-recumbent position in bed.Patient was connected 
to non-invasive ventilation, spontaneous –timed mode with low 
pressure setting of inspiratory pressure of 8 hpa, and expiratory 
pressure of 4 hpa, ramp of 10 minutes, rate depends upon 
patient respiratory rate. Low pressure settings will improve the 
patient compliance. 
10) Oxygen is connected through side port of non invasive 
ventilator tube if patient saturation is less than 88%- 92%.  
11) Interface is selected depending upon patient is comfort. During 
acute exacerbation Oronasal mask is the most preferred type of 
interface. 
12) Once NIV is started patients comfort, breathing synchrony with 
ventilator and patient compliance are important in determining 
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outcome.Synchrony between the ventilator and the patient is checked 
frequently because patients comfort and compliance is important for 
outcome. A clinical assessment of correct fitting of mask over the 
Oronasal region and degree of leakage of air (particularly on to the 
corneas) should be checked then and there. 
13) Once patient tolerates previous NIV settings, increment of IPAP 
should be done at a rate of approximately 5 cm H2O every 20 minutes, 
until upper limit of target pressure(20 cm H2O) is reached. 
14) Reassess all the parameters after 1 hour to decide about 
tolerability of the patient and response to treatment.  
15) Patient is monitored every 2 hours for first 12 hours and then every 
4 hours for next 36 hours. Monitoring is important to decide about 
treatment escalation to intubation.  
16) Bronchodilators administered preferably when patient is not 
connected to NIV machine, because delivery of both nebulized solutions 
and oxygen is affected by NIVpressure settings. If this is not possible 
then nebulizer can be connected between the expiration port and face 
mask.  
17) As per BTS guidelines even if patients work of breathing is 
improved   and  respiratory  rate  becomes  normal  in  a  few  hours,  NIV  
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therapy is continued for a minimum duration of 6 hours in order to 
prevent relapse. 
18) Patient who is still having increased work of breathing in 4 hours 
but improvement from baseline will continue NIV as much as possible 
in first day with break for food, and nebulisation. 
19) If Patient shows response, NIV is continued on second day during 
night time only.  
20) If patients condition is worsened (cardiac arrest or respiratory arrest, 
worsening of hypercapnia, loss of consciousness) from baseline, then 
mechanical ventilation was established. 
Data recording: 
Before administering NIV following parameters were recorded: 
1. Age and sex of the patient 
2. Childhood symptom  
3. Seasonal exacerbation  
4. Atopy 
5. Sputum consistency (mucoid / mucopurulent) 
6. Family history 
7. Smoking index, current smoker (yes / no) 
8. Sensorium 
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On examination: 
1. Vital parameter like heart rate, respiratory rate, blood pressure, 
spo2, were recorded 
2. Work of breathing  
3. Wheeze onauscultation  
4. Electrocardiogram, chest x ray, arterial blood gas analysis  
After administration of NIV the following data were recorded:  
1. Duration of NIV. 
2. Outcome  
Improvement defined as normalization of respiratory rate, no 
respiratory distress, normal heart rate, normal saturation, and 
work of breathing. 
Failure is defined as patient’s intolerance to non-invasive 
ventilation, requiring mechanical ventilation for survival and 
death during non-invasive ventilation.  
3. Duration of hospital stay. 
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ETHICAL JUSTIFICATION  
The various investigations and procedures that will be 
used in this study will be as per protocol. The identity of each 
patient will be kept confidential. This study will not violate 
medical ethics in anyway and it will help to know the role of 
non-invasive ventilation in patient with acute exacerbation of 
COPD 
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RESULTS 
 
Total number of 131 patients were enrolled in this study of which 
females were 32.1% and males 67.9%. Mean age of enrollment in this 
study is 54.85 (S.D +6.248), minimum age of the patient is 42, 
maximum age is 75. Mean age for male patient is 57.07 and for female 
patient is 48.97. 
  Frequency Percent 
Valid Female 42 32.1 
Male 89 67.9 
Total 131 100.0 
 
ATOPY: 
None of the study group members had history of Atopy. 
ATOPY HISTORY: 
  
Frequency Percent 
Valid No 131 100.0 
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CHILDHOOD SYMPTOMS: 
Childhood symptoms were present in one patient and who also had 
significant history of smoking.   
 
CHILDHOOD SYMPTOMS: 
  Frequency Percent 
Valid No 130 99.2 
Yes 1 .8 
Total 131 100.0 
 
 
FAMILY HISTORY:  
None of study group members had family history. 
FAMILY HISTORY: 
  Frequency Percent 
Valid No 131 100.0 
Total 131 100.0 
 
 
SEASONAL EXACERBATION: 
Seasonal exacerbation was found in 3 out of 131 patients. 
 
SEASONAL EXACERBATION: 
  Frequency Percent 
Valid No 128 97.7 
Yes 3 2.3 
Total 131 100.0 
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Mean pack years for males was found to be 29.26.females 
included in our study were non smokers. They had exposure to second 
hand smoking and biomass fumes exposure making them vulnerable to 
COPD. Mean duration of symptoms for male was 16.40 (S.D + 6.564). 
The mean duration of NIV was 19.44 (S.D + 13.889). Mean duration of 
hospital stay was 9.06 (S.D + 3.982) 
 
 
 
Age 
Pack 
years 
Duration
of symp 
in days 
Respirat
ory rate 
Duration
of NIV 
Duration 
of hospital 
stay 
N Valid 131 131 131 131 131 131 
Missi
ng 0 0 0 0 0 0 
Mean 54.85 19.89 16.40 32.26 19.44 9.06 
Median 56.00 30.00 14.00 32.00 26.00 9.00 
Mode 56 0 10a 34 26 5 
Std. 
Deviation 6.248 16.472 6.564 4.365 13.889 3.982 
Minimum 42 0 7 26 1 4 
Maximum 75 52 56 52 68 25 
 
While assessing consistency of sputum, 17 out of 131 patients had 
mucopurulent sputum and the remaining had mucoid sputum. We found 
that consistency of that Sputum had impact on the outcome of study i.e. 
improvement of symptoms or failure of treatment. But also we found 
that consistency of sputum do have impact on duration of NIV i.e.  
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Patients with mucopurulent sputum had longer duration of NIV than 
patients with mucoid sputum.  
SPUTUM PRODUCTION: 
 
  Frequency Percent 
Valid mucoid 114 87.0 
mucopurulent 17 13.0 
Total 131 100.0 
 
 
SPUTUM PRODUCTION OUTCOME 
 
 
   outcome 
Total    failure improved 
Sputumproduc
tion 
mucoid Count 8 106 114 
% of 
Total 6.1% 80.9% 87.0% 
mucopurul
ent 
Count 2 15 17 
% of 
Total 1.5% 11.5% 13.0% 
Total Count 10 121 131 
% of 
Total 7.6% 92.4% 100.0% 
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Linear Regression (between sputum production and duration of 
NIV) 
Variable Coefficie
nt 
Std 
Error 
F-test P-Value 
Sputumproduction 
(mucopurulent/muc
oid) 
13.087 3.437 14.4974 0.000216 
CONSTANT 17.737 1.238 14.4974 0.000000 
 
 
 
 
 
Chi-Square Tests 
 
Value df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-
Square .473
a 1 .492 .618 .382 
Continuity 
Correction .039 1 .843 
  
Likelihood 
Ratio .420 1 .517 .618 .382 
Fisher's Exact 
Test 
   .618 .382 
N of Valid 
Cases 131 
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LINEAR REGRESSION (Packyears = durationof NIV): 
 
Variable Coefficient Std 
Error 
F-test P-Value 
Durationof 
NIV 
0.227 0.102 4.8839 0.028873 
CONSTANT 15.483 2.445 40.0927 0.000000 
 
CURRENT SMOKING 
Current smoking history is present in 8.4% of study population; current 
smoking history has influence on NIV duration and outcome of 
treatment.                                             
      CURRENT SMOKER: 
  Frequency Percent 
Valid No 120 91.6 
Yes 11 8.4 
Total 131 100.0 
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CURRENT SMOKER OUTCOME 
   Outcome 
Total    failure improved 
Current 
smoker 
No Count 7 113 120 
% of 
Total 5.3% 86.3% 91.6% 
Yes Count 3 8 11 
% of 
Total 2.3% 6.1% 8.4% 
Total Count 10 121 131 
% of 
Total 7.6% 92.4% 100.0% 
 
 
 
Chi-Square Tests 
 
Value df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-
Square 6.569
a 1 .010 .039 .039 
Continuity 
Correction 3.880 1 .049 
  
Likelihood Ratio 4.412 1 .036 .039 .039 
Fisher's Exact 
Test 
   .039 .039 
N of Valid Cases 131     
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WHEEZE: 
 
Except for two patients all members of the study population had wheeze 
on auscultation. 
                                                      WHEEZE: 
  Frequency Percent 
Valid No 2 1.5 
Yes 129 98.5 
Total 131 100.0 
 
CO MORBIDITY: 
 
Seven members our study population had Co morbidities like diabetes, 
hypertension, Corpulmonale and coronary artery disease. Study also 
show that presence of Co morbidity has a significant influence on NIV 
outcome i.e. increased failure rate in NIV treatment.  
CO MORBIDITY: 
 
 
  Frequency Percent 
Valid CAD 1 .8 
   
corpulmonale 3 2.3 
DM 2 1.5 
HT 1 .8 
nil 124 94.7 
Total 131 100.0 
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                                   COMORBIDITY OUTCOME: 
 
   outcome 
Total    failure improved 
comorbidity CAD Count 1 0 1 
% of 
Total .8% .0% .8% 
DM Count 2 0 2 
% of 
Total 1.5% .0% 1.5% 
HT Count 0 1 1 
% of 
Total .0% .8% .8% 
corpulmonale Count 2 1 3 
% of 
Total 1.5% .8% 2.3% 
nil Count 5 119 124 
% of 
Total 3.8% 90.8% 94.7% 
Total Count 10 121 131 
% of 
Total 7.6% 92.4% 100.0% 
 
Chi-Square Tests 
 
Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. (2-
sided) 
Pearson Chi-
Square 53.491
a 4 .000 .000 
Likelihood Ratio 24.946 4 .000 .000 
Fisher's Exact Test 27.449   .000 
N of Valid Cases 131    
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ACCESSORY MUSCLE ACTIVITY: 
Increased respiratory rate was observed in almost all patients in our 
study group with increase accessory muscle activity except was one 
patient in whom muscle activity was not prominent due his obesity. 
ACCESSORY MUSCLE ACTIVITY: 
 
  Frequency Percent 
Valid No 1 .8 
Yes 130 99.2 
Total 131 100.0 
 
SENSORIUM: 
Since altered Sensorium was our exclusion criteria, all our subjects had 
of normal sensorium. 
SENSORIUM: 
  Frequency Percent 
Valid normal 131 100.0 
 
ELECTROCARDIOGRAM: 
 
Electrocardiogram was made as a mandatory investigation to our 
entire study group prior to NIV to exclude myocardial infarction. By 
doing this we detected three patients with Corpulmonale. ECG was also 
done during course of NIV treatment in isolated patients showing 
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symptoms and signs of MI. In this way we found patient with previous 
history of CAD on treatment and developed new MI leading to 
withdrawal of NIV therapy, showing that treatment outcome is poor in 
patients with co morbidities.ELECTROCARDIOGRAM: 
  Frequency Percent 
Valid    
normal 128 97.7 
   
p pulmonale 3 2.3 
Total 131 100.0 
 
                                          ECG OUTCOME: 
   Outcome 
Total 
   
Failure 
improve
d 
Ecg normal Count 8 120 125 
% of 
Total 6.1% 91.6% 97.7% 
p 
pulmonale 
Count 2 1 3 
% of 
Total 1.5% .8% 2.3% 
Total Count 10 121 131 
% of 
Total 7.6% 92.4% 100.0% 
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Chi-Square Tests 
 
Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. 
(2-sided) 
Pearson Chi-Square 15.345a 3 .002 .042 
Likelihood Ratio 7.391 3 .060 .042 
Fisher's Exact Test 9.505   .042 
N of Valid Cases 131    
 
CHEST X RAY: 
In chest x ray hyperinflation was predominant finding. 
CHEST X RAY  
 
  Frequency Percent 
 hyperinflation 
normal 
117 
11 
89.5 
8.3 
hyperinflation with cardiomegaly 1 .8 
pneumonia with hyperinflation 2 1.5 
Total 131 100.0 
 
CHEST X RAY OUTCOME: 
 
Crosstab 
   Outcome 
Total    failure Improved 
Cxr hyperinflation Count 7 121 127 
% of Total 5.3% 92.5% 97.8% 
hyperinflation with 
cardiomegaly 
Count 1 0 1 
% of Total .8% .0% .8% 
pneumonia with 
hyperinflation 
Count 2 0 2 
% of Total 1.5% .0% 1.5% 
Total Count 10 121 131 
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Crosstab 
   Outcome 
Total    failure Improved 
Cxr hyperinflation Count 7 121 127 
% of Total 5.3% 92.5% 97.8% 
hyperinflation with 
cardiomegaly 
Count 1 0 1 
% of Total .8% .0% .8% 
pneumonia with 
hyperinflation 
Count 2 0 2 
% of Total 1.5% .0% 1.5% 
Total Count 10 121 131 
% of Total 7.6% 92.4% 100.0% 
 
Chi-Square Tests 
 
Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. (2-
sided) 
Pearson Chi-
Square 37.281
a 5 .000 .002 
Likelihood Ratio 16.715 5 .005 .002 
Fisher's Exact Test 19.811   .002 
N of Valid Cases 131    
 
OUTCOME: 
 
Finally we record our finding that of 131 patients, 121 patients got 
improved with NIV treatment and remaining 10 patients failed to 
improve due to various reasons which are discussed below.  
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OUTCOME 
 
  Frequency 
Valid failure 10 
improved 121 
Total 131 
 
 
In this tab various parameters are compared with regard to success and 
failure, 1 indicates successand 0 indicates failure.  
 
outcome code  N Mean Std. Deviation 
Std. Error 
Mean 
Age 0 10 56.10 2.685 .849 
1 121 54.75 6.450 .586 
Durationofsympt
om in 
Days 
0 10 18.00 6.360 2.011 
1 121 16.26 6.589 .599 
Packyears 0 10 22.80 20.010 6.328 
1 121 19.64 16.222 1.475 
Heartrate 0 10 111.70 7.543 2.385 
1 121 99.57 8.174 .743 
Respiratoryrate 0 10 37.000 1.9437 .6146 
1 121 31.868 4.2816 .3892 
Hb 0 10 11.890 1.1020 .3485 
1 121 11.498 .8123 .0738 
Wbc 0 10 9500.00 2600.855 822.462 
1 121 8398.35 2065.268 187.752 
Durationofhospit
alstay 
0 10 17.90 3.985 1.260 
1 121 8.33 2.990 .272 
 
 
 
152 patients with increased respiratory rate with increased work of 
breathing and normal Ph (more than 7.35) admitted during study 
period                      
               131 patients enrolled in this study  
Subjected to NIV therapy and standard medical therapy 
18 patients recovered after 
standard medical therapy 
3 patient not given consent 
121 patients were 
improved after therapy 
10 patients were failed to 
improve with NIV therapy 
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REASON FOR FALIURE 
 
  Frequency Percent 
Valid  121 92.4 
ACUTE MYOCARDIAL 
INFARCTION 1 .8 
ASSOCIATED 
CORPULMONALE 2 1.5 
CLAUSTROPHOBIA AND 
FIGHTING AGAINST 
VENTILATOR 
4 3.1 
MECHANICALLY 
VENTILATED-DEATH 1 .8 
NECROTISING 
PNEUMONIA 1 .8 
PARAPNEUMONIC 
EFFUSION 1 .8 
Total 131 100.0 
 
The above mentioned parameters are the important reasons that led to 
failure in our treatment. 
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DISCUSSION 
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In this prospective observational study totally 131 patients with 
increased work of breathing and increased respiratory rate (> 24/min) 
with normal Ph (>7.35) were enrolled in our study, of which32.1% were 
females and 67.9% were males.  Mean age of enrollment in this study is 
54.85 (S.D +6.248), minimum age of the patient is 42, maximum age is 
75. Mean age for male patient is 57.07 and for female patient is 48.97. 
The patients were subjected to NIV treatment in the general ward itself 
which was convenient, cost effective, feasible and alleviating need for 
intensive care settings. 
COPD patients with acute exacerbation will have increased 
respiratory rate. If this stage is left untreated, the disease may progress 
to acute respiratory failure. When NIV is combined with standard 
medical treatment duration of hospital stay is reduced, recovery from 
illness is faster, thereby improving their disease outcome. Compared to 
stable COPD patients, unstable COPD patients are more prone for 
hypercapnic respiratory failure, hence there is need to start NIV therapy 
early. Reason for not administrating oxygen therapy in patients with 
spo2 > 88% as first line therapy is that such an act will blunt hypoxic 
ventilatory drive further worsening exacerbation. Hence patients with 
spo2 >88% were not subjected to oxygen therapy.  In review of past 
studies we found that most of the studies were done in patients with 
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respiratory acidosis (ph 7.25-7.35) but relatively few studies are 
available on patients with ph> 7.35. In our study we have included 
COPD patients with acute exacerbation, ph>7.35 and documented NIV 
outcome with respect to success or failure in them. 
In our study we followed BTS guidelines and set minimum duration of 
NIV therapy as six hours and made the following observations: 
(a) In patients with respiratory rate < 30, minimum of six hours of 
therapy was administered even if patients recovered earlier in 
order to avoid relapse.  
(b) In patients with respiratory rate 30 – 40, NIV was administered 
during day time and sleep (excluding time for physiotherapy, 
nebulisation, and personal activities). If significant improvement 
with minimal increase in work of breathing, patient was 
supported with NIV during next day sleep alone, but if no 
satisfactory improvement is attained NIV is continued next day 
both during day and sleep till improvement is reached.(The 
maximum duration of NIV therapy observed in our study is 3-4 
days) 
While considering the intolerance level to NIV therapy among 
various studies, it is drawn that this rate is highly variable and the 
reason for which is not studied. Pertaining to this aspect we took much 
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effort to reduce the rate of intolerance, patients were given good 
counseling regarding positive benefits of receiving the therapy thereby 
alleviating their claustrophobia and anxiety. In spite of such an 
immense effort patients who were still fighting with ventilator, we set 
the escalation of inspiratory positive pressure (RAMP) at 20 min and 
slowly brought it down to their peer group rate. Thus achieving the goal 
of reduction in intolerance level. Above all these efforts, four patients 
continued to be claustrophobic, detaining from our study. 
 
We found in our study that applying NIV therapy in patients with 
increase in respiratory rate adequately prevents them from progressing 
to acute respiratory failure, thereby reducing duration of hospital stay 
and need for mechanical ventilation. Mean duration of NIV to revoke 
patients with acute exacerbation and increased respiratory rate to near 
normalcy was 19.44 hours, duration of NIV treatment is individualized 
and depends upon following factors: 
1. Respiratory rate at the time of admission  
2. Sputum consistency 
3. Current history of smoking 
4. Presence of co morbidities like Corpulmonale, diabetes and 
coronary artery disease. 
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I would like to high light a few important parameters and their 
significance with duration of NIV therapy  
Sputum consistency – patients with mucopurulent sputum had 
longer duration therapy compared to patients with mucoid sputum, and 
these patients with mucopurulent sputum had also received concomitant 
antibiotic therapy. 
Pack years- not much significance has been observed   
Current smoking – patients who smoke still datecoming with 
exacerbation when subjected to therapy we observed that duration of 
treatment and hospital stay is increased. 
Co morbidities – compared to isolated patients with COPD, 
patients with co morbidities need close monitoring, additional nursing 
care, corresponding medical therapy thereby influencing outcome of 
therapy. As COPD is common among old age people as is true for co 
morbidities also, considering our outcome we strongly recommend that 
such patients need close observation in high intensive unit keeping in 
mind the possibility of need for mechanical ventilation. 
We also studied the reason behind failure of NIV therapy in some 
patients in our group, finalizing our analysis here are the important 
reasons: Claustrophobia (4 patients), acute myocardial infarction 
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(1patient), associated corpulmonale (2 patients), diabetes with 
pneumonia complication (2 patients)   
Patients with claustrophobia where treated with medical therapy 
and were closely monitored for signs of respiratory failure, they stayed 
in hospital for longer duration but finally got improved and were 
discharged. One patients with previous CAD history developed MI 
during course of NIV therapy hence NIV therapy was stopped, MI 
treatment was prioritized and medical therapy was continued.  
Two patients with diabetes developed pneumonia, for them 
pneumonia was treated and NIV therapy was given for longer time. Two 
Patients with Corpulmonale required longer duration of NIV therapy. 
Limitations of the study are: 
My study is an observational study; we need a randomized control 
study to conform the influencing factor on NIV therapy 
This study was conducted to know the outcome of NIV therapy in 
patients with acute exacerbation of COPD. Long term follows up and 
relapse rate were not studied. 
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Conclusion: 
COPD with acute exacerbation is treated till now with medical 
therapy and ventilatory support. Our field has seen in recent past years 
few researches done on NIV therapy in patients with acute exacerbation 
of COPD with ph>7.35. This study is one among them. If NIV therapy 
is administered earlier in patients with acute exacerbation of COPD, we 
can certainly reduce the duration of NIV treatment, duration of hospital 
stay, and thereby reducing cost of treatment. 
We also strongly put forward that in patients with associated co 
morbidity failure rate is higher with NIV therapy and utmost care should 
be taken to control co morbid conditions and start other options like 
mechanical ventilation whenever needed. 
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reasonforfailure
1 munnusamy 65 male 14 No No No No 30 mucoid No Yes nil Yes normal 98 13080 40 36.7 62.4 7.38 normal 13.5 26 hyperinflation 8500 improved 7
2 thiyachallam 52 male 10 No No No No 35 mucoid No Yes nil Yes normal 96 11070 27 32.6 63.4 7.39 normal 11.6 6 hyperinflation 9100 improved 4
3 shankar 53 male 15 No No No No 37 mucoid No Yes corpulmonale Yes normal 98 12080 33 38.5 65.4 7.37 p pulmonale 13.6 48 hyperinflation 8600 improved 7
4 murugan 45 male 25 No No No No 10 mucopurulent No Yes nil Yes normal 98 12070 28 41.6 67.8 7.36 normal 11.2 48 HYPERINFLATION 12500 improved 10
5 VELLAYUDHAM 72 male 7 No No No No 30 mucoid No Yes nil Yes normal 88 12080 33 40.3 64.7 7.39 NORMAL 10.7 20 hyperinflation 8700 improved 6
6 sakthivel 49 male 13 No No No No 25 mucoid No Yes nil Yes normal 104 13070 28 38.2 68.3 7.41 normal 12.3 6 hyperinflation 9100 improved 7
7 kannan 75 male 14 No No No No 0 mucoid No Yes nil Yes normal 121 12080 40 28.4 62.5 7.42 normal 12.8 32 hyperinflation 11400 improved 10
8 murugan 58 male 14 No No No No 35 mucoid No Yes nil Yes normal 127 11070 52 29.4 61.2 7.41 normal 12.4 44 hyperinflation 9300 improved 12
9 krishnan 65 male 15 No No No No 0 mucoid No Yes nil Yes normal 123 12080 28 27.6 71.3 7.39 normal 12.3 6 hyperinflation 9600 improved 4
10 ayyam perumal 69 male 21 No No No No 32 mucoid No Yes nil Yes normal 108 12080 33 32.4 68.4 7.4 normal 13.4 26 hyperinflation 10300 improved 6
11 ramaraj 57 male 30 No No No No 35 mucoid No Yes nil Yes normal 88 13080 29 35.7 72.3 7.41 normal 12.3 6 hyperinflation 8700 improved 6
12 dhanapal 60 male 10 No No No No 30 mucoid No Yes nil Yes normal 136 13090 42 34.5 68.2 7.42 normal 11.9 44 hyperinflation 8500 improved 8
13 egambarm 52 male 25 No No No No 37 mucoid No Yes nil Yes normal 88 13070 36 36.3 62.6 7.43 normal 11.2 26 hyperinflation 9100 improved 10
14 shanthi 52 female 10 No No No No 0 mucoid No Yes nil Yes normal 105 12070 34 37.2 64.3 7.41 normal 12.3 26 hyperinflation 11400 improved 8
15 girija 42 female 12 No No No No 0 mucoid No Yes nil Yes normal 98 11070 28 35.4 65.3 7.39 normal 10.3 6 hyperinflation 8600 improved 12
16 abirami 45 female 13 No No No No 0 mucoid No Yes nil Yes normal 102 10070 34 28.4 68.2 7.38 normal 10.6 26 hyperinflation 8500 improved 14
17 rani 46 female 16 No No No No 0 mucoid No Yes nil Yes normal 96 12080 29 29.3 67.3 7.39 normal 9.8 6 hyperinflation 8700 improved 6
18 bhavani 56 female 14 No No No No 0 mucoid No Yes nil Yes normal 114 11080 34 28.3 64.3 7.36 normal 9.6 26 hypereinflation 8600 improved 9
19 munusamy 62 male 20 No No No No 32 mucoid No Yes nil Yes normal 108 13070 36 30.4 64.8 7.35 normal 11.6 26 hyperinflation 9200 improved 12
20 knadasamy 59 male 15 No No No No 34 mucopurulent No Yes nil Yes normal 98 13090 36 31.4 67.2 7.38 normal 12.3 36 hyperinflation 13200 improved 16
21 karthik 54 male 21 No No No No 28 mucoid Yes Yes nil Yes normal 96 12070 28 37.2 69.3 7.39 normal 11.4 20 hyperinflation 10400 improved 10
22 shanmugam 61 male 18 No No No No 30 mucoid No Yes nil Yes normal 102 13090 32 38.4 62.7 7.4 normal 12.3 26 hyperinflation 6400 improved 10
23 karupusamy 62 male 16 No No No No 34 mucoid No Yes nil Yes normal 96 12070 38 39.5 66.4 7.41 normal 10.4 26 hyperinflation 11400 improved 12
24 marappan 63 male 22 No No No No 32 mucoid No Yes nil Yes normal 102 13080 34 36.7 65.7 7.39 hyperinflation 10.4 26 hyperinflation 11200 improved 15
25 varathan 64 male 24 No No No No 28 mucoid No Yes nil Yes normal 106 13080 29 35.6 68.2 7.38 normal 11.4 6 hyperinflation 6700 improved 9
26 chinnappan 56 male 18 No No No No 32 mucoid No Yes nil Yes normal 104 13080 36 37.2 69.2 7.39 normal 12.3 26 hyperinflation 5600 improved 13
27 annamalai 55 male 20 No No No No 28 mucoid No Yes nil Yes normal 96 12070 32 36.9 63.6 7.36 normal 11.3 26 hyperinflation 7800 improved 10
28 vijaya 50 female 10 No No No No 0 mucopurulent No Yes nil Yes normal 106 11080 31 36.8 62.4 7.35 normal 10.2 36 hyperinflation 11800 improved 15
29 radhakrishnan 52 male 20 No No No No 30 mucoid No Yes nil Yes normal 102 12070 27 36.7 67.3 7.37 normal 11.2 6 hyperinflation 8600 improved 5
30 rajeshwari 52 female 14 No No No No 0 mucoid No Yes nil Yes normal 94 12070 34 38.5 65.8 7.38 normal 10.1 26 hyperinflation 7800 improved 15
31 jayachandran 56 male 24 No No No No 34 mucoid No Yes nil Yes normal 96 13080 29 41.6 66.9 7.37 normal 12.3 6 hyperinflation 7700 improved 7
32 anand 52 male 26 No No No No 26 mucoid No Yes nil Yes normal 98 11070 30 42.6 71.3 7.38 normal 10.5 6 hyperinflation 7600 improved 7
33 sathiya 43 female 12 No No No No 0 mucoid No Yes nil Yes normal 97 11080 34 40.1 62.8 7.39 normal 11.2 26 hyperinflation 7300 improved 9
34 madappan 52 male 16 No No No No 32 mucoid No Yes nil Yes normal 108 14080 26 36.4 68.3 7.37 normal 11.3 6 hyperinflation 8200 improved 5
35 andal 45 female 13 No No No No 0 mucoid No Yes nil No normal 92 13080 28 34.5 64.5 7.41 normal 12.2 6 hyperinflation 8300 improved 5
36 ashokkumar 52 male 12 No No No No 36 mucopurulent No Yes nil Yes normal 104 13080 32 33.5 65.7 7.4 normal 10.3 30 hyperinflation 7600 improved 7
37 pushpharani 47 female 12 No No No No 0 mucopurulent No Yes nil Yes normal 97 12080 30 36.3 67.5 7.4 normal 11.3 26 hyperinflation 5600 improved 7
38 chandra 48 female 22 No No No No 0 mucoid No Yes nil Yes normal 84 12080 27 37.3 69.3 7.41 normal 11.5 6 hyperinflation 7800 improved 5
39 pandiyarajan 54 male 24 No No No No 35 mucoid No Yes nil Yes normal 86 13080 34 27.4 63.6 7.41 normal 12.3 26 hyperinflation 6700 improved 7
40 nandakumar 56 male 14 No No No No 34 mucoid No Yes nil Yes normal 92 12070 34 28.3 65.8 7.42 normal 12.3 26 hyperinflation 7900 improved 8
41 raja 50 male 16 No No No Yes 30 mucoid No Yes nil Yes normal 96 12080 27 31.4 67.2 7.43 normal 11.9 6 hyperinflation 6700 improved 5
42 sakthivel 62 male 17 No No No No 38 mucoid Yes Yes nil Yes normal 98 13080 26 36.2 61 7.44 normal 10.3 6 hyperinflation 7500 improved 5
43 chinnarasu 48 male 10 No No No No 28 mucoid No Yes nil Yes normal 102 13080 29 35.8 63.5 7.45 normal 11.7 6 hyperinflation 8500 improved 5
44 rajamanikam 44 male 15 No No No No 24 mucoid No Yes nil Yes normal 96 13080 28 36.5 68.3 7.43 normal 13.1 6 hyperinflation 6800 improved 6
45 muthukrishnan 46 male 14 No No No No 26 mucoid No Yes nil Yes normal 110 13070 34 37.2 63.7 7.42 normal 12.6 30 hyperinflation 11200 improved 9
46 vanitha 45 female 12 No No No No 0 mucoid No Yes nil Yes normal 90 12080 38 36.7 62.5 7.41 normal 10.1 26 hyperinflation 5700 improved 8
47 vendamani 52 female 14 No No No No 0 mucoid No Yes nil Yes normal 96 13080 34 34.6 67.3 7.42 normal 11.1 26 hyperinflation 6800 improved 8
48 arulmani 62 male 15 No No No No 34 mucoid No Yes nil Yes normal 102 13080 29 28.5 63.6 7.42 normal 12.1 6 hyperinflation 7300 improved 5
49 revathy 48 female 14 No No No No 0 mucoid No Yes nil Yes normal 96 11080 34 29.4 68.4 7.37 normal 11.1 26 hyperinflation 7200 improved 9
50 natesan 57 male 12 No No No No 34 mucopurulent No Yes nil Yes normal 102 12080 32 31.2 69.3 7.38 normal 12.3 36 hyperinflation 12300 improved 12
51 kumar 64 male 15 No No No No 0 mucoid No Yes nil Yes normal 92 12080 28 33.5 62.7 7.39 normal 11.2 6 hyperinflation 8700 improved 6
52 murugan 61 male 10 No No No No 32 mucoid No Yes nil Yes normal 94 13080 36 32.6 64.8 7.36 normal 11.4 26 hyperinflation 8600 improved 8
53 mohammed nisha 56 male 13 No No No No 36 mucoid No Yes nil Yes normal 96 13080 36 35.3 63.7 7.36 normal 13.2 26 hyperinflation 5600 improved 10
54 raman 62 male 8 No No No No 39 mucoid No Yes nil Yes normal 90 11080 30 38.4 67.3 7.37 normal 11.4 6 hyperinflation 6400 improved 6
55 ramesh 57 male 14 No No No No 34 mucoid No Yes nil Yes normal 89 11080 32 26.9 69.3 7.37 normal 11.4 26 hyperinflation 6700 improved 8
56 selvam 56 male 13 No No No No 34 mucoid No Yes nil Yes normal 106 12090 27 29.5 65.7 7.38 normal 11.3 6 hyperinflation 7600 improved 5
57 bama 43 female 9 No No No No 0 mucopurulent No Yes nil Yes normal 94 11080 34 30.6 65.8 7.38 normal 11.2 26 hyperinflation 5800 improved 10
58 anjalai 58 female 20 No No No No 0 mucoid No Yes nil Yes normal 94 11070 29 35.7 67.3 7.39 normal 11.3 6 hyperinflation 7800 improved 5
59 abibula 54 male 23 No No No No 28 mucoid No Yes nil Yes normal 102 11080 32 37.6 64.7 7.39 normal 12.3 26 hyperinflation 8900 improved 12
60 ganesan 58 male 30 No No No No 32 mucoid No Yes nil Yes normal 92 11070 28 38.9 68.3 7.37 normal 12.1 6 hyperinflation 8200 improved 6
61 muthukrishnan 53 male 25 No No No No 0 mucoid No Yes nil Yes normal 94 11070 29 30.2 64.6 7.41 normal 12.3 6 hyperinflation 6700 improved 5
62 pusharani 62 male 12 No No No No 32 mucoid No Yes nil Yes normal 104 12080 36 40.2 67.4 7.41 normal 12.7 26 hyperinflation 6900 improved 8
63 chandran 62 male 10 No No No No 35 mucoid Yes Yes nil Yes normal 108 13090 40 41.6 68.3 7.41 normal 13.2 26 hyperinflation 8700 improved 10
64 mani 45 male 16 No No No No 20 mucoid No Yes nil Yes normal 97 13090 27 42.5 65.3 7.37 normal 11.3 6 hyperinflation 8300 improved 5
65 ugenpaul 58 male 14 No No No No 30 mucoid No Yes nil Yes normal 102 11080 32 45.2 67.9 7.36 normal 11.4 26 hyperinflation 7300 improved 9
66 sathya 47 female 24 No No No No 0 mucoid No Yes nil Yes normal 103 13090 38 41.3 63.5 7.37 normal 11.3 26 hyperinflation 11200 improved 11
67 madappan 57 male 26 No No No No 32 mucoid No Yes nil Yes normal 102 11080 32 40.5 67.8 7.38 normal 11.2 26 hyperinflation 7400 improved 6
68 govindasamy 62 male 20 No No No No 34 mucoid No Yes nil Yes normal 102 13090 36 37.3 65.8 7.39 normal 12.3 26 hyperinflation 6200 improved 10
69 arokiyamani 56 male 16 No No No No 52 mucoid No Yes nil Yes normal 98 12070 28 38.4 63.5 7.38 normal 11.2 6 hyperinflation 6500 improved 7
70 mary 49 female 10 No No No No 0 mucoid No Yes nil Yes normal 107 13080 38 39.5 67.4 7.36 normal 11.4 26 hyeprinflation 6300 improved 9
71 narayanan 54 male 25 No No No No 34 mucoid No Yes nil Yes normal 110 12080 34 36.4 68.3 7.38 normal 12.1 26 hyperinflation 6700 improved 9
72 rajendren 51 male 10 No No No No 25 mucoid No Yes nil Yes normal 98 11080 29 37.4 69.2 7.41 normal 11.3 6 hyperinflation 5400 improved 6
73 vasudevan 57 male 15 No No No No 36 mucopurulent No Yes nil Yes normal 105 13090 36 38.4 62.6 7.42 normal 12.4 36 hyperinflation 13200 improved 14
74 ravi 62 male 21 No No No No 31 mucoid No Yes nil Yes normal 101 12090 32 38.4 67.4 7.41 normal 11.2 26 hyperinflation 8700 improved 8
75 joshi 49 female 15 No No No No 0 mucoid No Yes nil Yes normal 98 12080 32 30.1 63.7 7.42 normal 11 26 hyperinflation 8200 improved 10
76 venkat 56 male 18 No No No No 32 mucoid No Yes nil Yes normal 108 12080 39 29.5 63.9 7.43 normal 11.4 26 hyperinflation 7500 improved 11
77 veni 52 female 10 No No No No 0 mucoid No Yes nil Yes normal 90 11080 28 31.5 67.3 7.44 normal 11.2 6 hyperinflation 8100 improved 6
78 stephen 52 male 10 No No No No 0 mucoid No Yes nil Yes normal 90 11080 27 33.8 64.8 7.45 normal 11.2 6 hyperinflation 8300 improved 5
79 sumathi 56 male 56 No No No No 31 mucoid No Yes nil Yes normal 102 12080 34 36.4 67.9 7.38 normal 12.1 26 hyperinflation 7300 improved 9
80 bharathi 52 female 13 No No No No 0 mucoid No Yes nil Yes normal 92 11080 34 37.4 63.5 7.39 normal 11.4 26 hyperinflation 6800 improved 11
81 chakaravarthi 56 male 14 No No No No 35 mucoid No No nil Yes normal 96 12080 32 38.6 68.3 7.38 normal 11.2 26 hyperinflation 5600 improved 9
82 munniyan 56 male 22 No No No No 32 mucoid No Yes nil Yes normal 108 11070 34 36.7 67.4 7.37 normal 11.3 26 hyperinflation 8900 improved 9
83 pushpha 45 female 14 No No No No 0 mucoid No Yes nil Yes normal 92 11080 26 41.3 69.3 7.36 normal 11.2 6 hyperinflation 5400 improved 6
84 prema 46 female 10 No No No Yes 0 mucoid No Yes nil Yes normal 102 11070 34 40.3 63.7 7.38 normal 11.2 26 hyperinflation 7500 improved 9
85 krishnan 52 male 26 No No No No 30 mucoid No Yes nil Yes normal 98 11080 27 40.2 69.2 7.39 normal 11.2 6 hyperinflation 8200 improved 5
86 shankar 57 male 10 No No No No 30 mucopurulent No Yes nil Yes normal 102 11070 34 41.3 64.7 7.36 normal 10.2 26 hyperinflation 7100 improved 10
87 ambal 49 female 12 No No No No 0 mucoid No Yes nil Yes normal 104 12080 36 26.7 68.1 7.41 normal 12.3 26 hyperinflation 7500 improved 10
88 kavitha 56 female 20 No No No No 0 mucopurulent No Yes nil Yes normal 112 12080 40 37.2 67.8 7.4 normal 11.4 36 hyperinflation 12400 improved 13
89 mathin 56 male 20 No No No No 0 mucoid No Yes nil Yes normal 92 11080 26 38.9 63.4 7.42 normal 12.3 6 hyperinflation 7200 improved 5
90 shanmugam 57 male 21 No No No No 34 mucoid No Yes nil Yes normal 90 12090 27 34.6 67.3 7.41 normal 13.2 6 hyperinflation 6500 improved 5
91 lakshmi 46 female 14 No No No No 0 mucoid No Yes nil Yes normal 93 11070 28 32.4 68.3 7.42 normal 11.5 6 hyperinflation 8400 improved 6
92 settu 54 male 35 No No No No 28 mucoid No Yes nil Yes normal 94 11080 30 33.6 69.2 7.45 normal 11.2 6 hyperinflation 7800 improved 5
93 adhimoolam 57 male 20 No No No No 32 mucoid No Yes nil Yes normal 94 12090 29 31.5 67.8 7.37 normal 11.7 6 hyperinflation 11000 improved 6
94 annai 52 female 10 No No No No 0 mucoid No Yes nil Yes normal 95 11080 26 30.4 69.3 7.36 hyperinflation 11.3 6 hyperinflation 11000 improved 5
95 kanagaraj 52 male 12 No No No No 32 mucoid No Yes nil Yes normal 102 12090 36 38.5 65.2 7.38 normal 10.2 26 hyperinflation 6400 improved 9
96 latha 47 female 13 No No No No 0 mucoid No Yes nil Yes normal 98 11080 29 41.3 71.4 7.38 normal 11 6 hyperinflation 8700 improved 5
97 nalini 48 female 14 No No No No 0 mucoid Yes Yes nil Yes normal 102 11080 34 45.2 69.2 7.36 normal 11.2 26 hyperinflation 10200 improved 8
98 rajammal 56 female 10 No No No No 0 mucoid No Yes nil Yes normal 92 11080 27 41.3 67.4 7.39 normal 11.3 6 hyperinflation 6700 improved 5
99 marappan 69 male 21 No No No No 38 mucopurulent No Yes nil Yes normal 110 13090 34 42.3 68.3 7.4 normal 11.2 36 hyperinflation 13400 improved 14
100 munniyan 56 male 10 No No No No 34 mucoid Yes Yes nil Yes normal 103 11080 32 43.2 69.2 7.42 normal 10.2 38 hyperinflation 12700 improved 12
101 sarathy 48 female 10 No No No No 0 mucopurulent No Yes nil Yes normal 98 11080 28 37.3 62.5 7.44 normal 11.3 26 hyperinflation 12500 improved 10
102 pappathi 52 female 10 No No No No 0 mucoid No No nil Yes normal 96 11080 28 38.5 61.8 7.37 normal 11.2 6 hyperinflation 5800 improved 6
103 arun 56 male 15 No No No No 34 mucoid Yes Yes HT Yes normal 110 14080 35 40.1 64.3 7.38 normal 11.2 36 hyperinflation 7300 improved 12
104 geetha 56 female 10 No No No No 0 mucoid No Yes nil Yes normal 96 11080 28 42.5 67.3 7.39 normal 11.3 6 hyperinflation 5600 improved 6
105 ramachandren 62 male 14 No No No No 31 mucoid No Yes nil Yes normal 98 11080 30 34.5 64.5 7.37 normal 11.2 6 hyperinflation 7800 improved 5
106 suresh 57 male 13 No No No No 0 mucoid No Yes nil Yes normal 98 11080 28 45.3 64.5 7.38 normal 11 6 hyperinflation 5600 improved 5
107 palani 45 male 12 No No No No 25 mucopurulent No Yes nil Yes normal 102 11080 28 35.2 68.3 7.42 normal 11.2 26 hyperinflation 9800 improved 10
108 chandren 56 male 12 No No No No 30 mucoid No Yes nil Yes normal 98 13090 34 36.8 67.8 7.43 normal 11.2 26 hyperinflation 6700 improved 10
109 bhavani 47 female 12 No No No No 0 mucoid No Yes nil Yes normal 96 11080 34 34.7 69.3 7.44 normal 11.7 26 hyperinflation 9500 improved 10
110 krishnan 62 male 12 No No No No 36 mucoid Yes Yes nil Yes normal 110 11080 34 34.5 67.4 7.45 normal 11.5 36 hyperinflation 9700 improved 13
111 senthil 62 male 10 No No No No 34 mucoid No Yes nil Yes normal 104 12080 32 31.1 65.3 7.36 normal 10.2 26 hyperinflation 7800 improved 10
112 lakshmi 58 female 12 No No No No 0 mucoid No Yes nil Yes normal 94 11070 29 37.2 67.4 7.37 normal 12.3 6 hyperinflation 6400 improved 5
113 bharani 64 male 14 No No No No 34 mucoid No Yes nil Yes normal 104 13080 38 38.2 68.2 7.43 normal 10.3 26 hyperinflation 11800 improved 10
114 kannan 62 male 18 No No No No 0 mucoid No Yes nil Yes normal 92 11070 30 45.3 68.3 7.39 normal 10.9 6 hyperinflation 7400 improved 6
115 krishnaveni 52 female 15 No No No No 0 mucoid No Yes nil Yes normal 90 11070 27 31.2 69.3 7.4 normal 10.8 6 hyperinflation 5600 improved 5
116 harichandran 56 male 20 No No No No 35 mucopurulent No Yes nil Yes normal 105 13090 32 34.2 67.8 7.41 normal 11.4 46 hyperinflation 13700 improved 14
117 madhavan 56 male 25 No No No No 40 mucoid Yes Yes nil Yes normal 104 11080 32 35.5 67.8 7.42 normal 12.3 46 hyperinflation 6700 improved 12
118 vendhan 61 male 28 No No No No 39 mucopurulent No Yes nil Yes normal 108 11070 36 34.4 64.7 7.38 normal 12.3 46 hyperinflation 13300 improved 15
119 balakrishnan 58 male 20 No No No No 0 mucoid No Yes nil Yes normal 94 11070 29 34.6 65.7 7.37 normal 11.2 6 hyperinflation 11200 improved 6
120 shankari 49 female 13 No No No No 0 mucoid No Yes nil Yes normal 88 11080 26 36.7 64.7 7.45 normal 11.4 6 hyperinflation 9200 improved 5
121 ganthi 56 female 14 No No No No 0 mucoid No Yes nil Yes normal 84 11080 28 37.3 68.3 7.4 normal 10.4 6 hyperinflation 6200 improved 5
122 anjali 58 female 15 No No No No 0 mucopurulent No Yes DM Yes normal 108 11070 38 36.9 67.2 7.41 normal 11.2 4
pneumonia with 
hyperinflation 14500 failure 31 NECROTISING PNEUMONIA
123 elumalai 54 male 25 No No No No 45 mucoid Yes Yes nil Yes normal 121 14070 38 35.7 65.7 7.42 normal 13.5 1 hyperinflation 7800 failure 28 CLAUSTROPHOBIA
124 krishnan 62 male 14 No No No No 35 mucoid Yes Yes nil Yes normal 110 13090 36 32.3 67.8 7.37 normal 12.3 4 hyperinflation 5400 failure 10
MECHANICALLY 
VENTILATED-DEATH
125 ganesan 56 male 30 No No No No 38 mucoid No Yes corpulmonale Yes normal 110 14070 38 37.8 69.2 7.38 p pulmonale 11.3 58 hyperinflation 9600 failure 25
ASSOCIATED 
CORPULMONALE
126 shangari 52 female 12 No No No No 0 mucoid No Yes nil Yes normal 98 11080 34 36.4 65.7 7.39 normal 11.2 1 hyperinflation 7800 failure 30 CLAUSTROPHOBIA
127 arumugam 57 male 14 No No No No 38 mucoid No Yes nil Yes normal 112 12080 40 32.3 64.7 7.38 normal 11.4 1 hyperinflation 10200 failure 29 CLAUSTROPHOBIA
128 rajan 56 male 18 No No No No 30 mucopurulent No Yes DM Yes normal 108 13090 38 37.4 68.3 7.36 normal 11.3 4
pneumonia with 
hyperinflation 12800 failure 31
PARAPNEUMONIC 
EFFUSION
129 sumathi 56 female 12 No No No No 0 mucoid No Yes nil Yes normal 108 13080 34 38.4 64.6 7.35 normal 10.3 1 hyperinflation 9800 failure 30 CLAUSTROPHOBIA
130 kamatachi 56 female 25 No No No No 0 mucoid No Yes corpulmonale Yes normal 124 13080 36 38.4 62.7 7.39 p pulmonale 12.8 68
hyperinflation 
with cardiomegaly 8600 failure 28
ASSOCIATED 
CORPULMONALE
131 saravanan 54 male 15 No Yes No Yes 42 mucoid Yes Yes CAD Yes normal 118 14080 38 36.3 61.7 7.41 normal 13.6 4 hyperinflation 8500 failure 18
ACUTE MYOCARDIAL 
INFARCTION
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